

520,820

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



07 JAN 2005



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
WO 2004/005535 A2

(51) International Patent Classification<sup>7</sup>:

C12Q 1/02

(21) International Application Number:

PCT/EP2003/008209

(22) International Filing Date: 9 July 2003 (09.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02 08 636 9 July 2002 (09.07.2002) FR

(71) Applicant (for all designated States except US): MUTABILIS [FR/FR]; 156, Avenue Vaugirard, F-75730 PARIS CEDEX 15 (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ESCAICH, Sonia [FR/FR]; 13, Rue de Toul, F-75012 PARIS (FR).

(74) Agents: PEAUCELLE, Chantal et al.; Cabinet ARMENGAUD AINE, 3, Avenue Bugeaud, F-75116 PARIS (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/005535 A2

(54) Title: PATHOGENICITY DETERMINANTS WHICH CAN BE USED AS TARGETS FOR DEVELOPING MEANS FOR PREVENTING AND CONTROLLING BACTERIAL INFECTIONS AND/OR SYSTEMIC DISSEMINATION

(57) Abstract: The invention relates to a method for identifying and selecting a gene required for the proliferation *in vivo* of a pathogenic microorganism, comprising :- using a strain of the pathogenic microorganism, - generating mutants for inactivation in the genes encoding these factors, - determining the virulence of these mutants on an experimental model of infection, and their effect on enteric colonization in an axenic mouse model, and - selecting the bacterial genes essential for resistance to serum *in vitro*, and essential, in the host, for dissemination in the serum. Application to the screening of compounds which inhibit the products of the genes identified, and to the inhibition *in vitro* of the proliferation of a pathogenic microorganism in serum.

BEST AVAILABLE COPY

Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination

The invention relates to pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination.

5

Current treatments for infectious diseases of bacterial origin are based on the inhibition of essential bacterial targets *in vitro* using antibiotics. These targets are conserved in many bacterial species and make it possible to treat various types 10 of infection. However, broad-spectrum antibiotics are active on the host's commensal flora, which promotes the acquisition and transfer of mechanisms of resistance to these antibiotics, hence a limiting of the effectiveness of current treatments with antibiotics. A need therefore exists for novel 15 antibacterial treatments.

In this regard, the invention provides a novel strategy, the aim of which is to specifically target pathogenic bacteria without significantly altering their growth at their portal of 20 entry into the host organism, where they are in a situation of commensalism. These pathogens are in particular the bacteria responsible for serious systemic infections, such as *E.coli*, in general *Enterobacteria*, *Pseudomonas*, *Acinetobacter*, *Moraxella* and *Neisseria* and, for the gram positives, the 25 bacteria of the genus *Staphylococcus*, *Enterococcus* and *Streptococcus*.

It is known, specifically, that the bacteria responsible for 30 serious infections are capable of growth in the presence of serum and are resistant to the bactericidal action of

- 2 -

complement. This resistance allows dissemination of the infection, via the blood, to the various tissues of the host's body.

5 The ability of bacteria to grow in human serum is due to different pathogenicity/virulence factors. Among those frequently cited, mention will be made of the physical barrier, represented by the capsule, for access of complement to the bacterial membrane, the sialic acids of the capsule or  
10 of the O antigen which promote binding of factor H to c3b, and particular surface proteins such as PorA (*Neisseria gonorrhoeae*), YadA (*Yersinia pestis*) or protein M (*Streptococcus pyogenes*), which bind factor H, all these factors preventing complement activation.

15 Other proteins expressed or bound by the pathogens have proved to be important for resistance to complement and cause cleavage of complement factors or inhibit their binding to the surface of the bacterium (Rautemaa R.; Meri S., *Microbes and*  
20 *Infection* 1999, 1:785:794).

The lipopolysaccharide (LPS) of gram-negative bacteria is known to be a virulence factor, but the role of its various constituents on the resistance to serum has not been  
25 established for all bacterial species. For example, in some studies in *E.coli*, the O antigen is considered to be determinant (Burns S.M. Hull S.I. *Infect Immun*, 1998, Sept 66(9):4244-53); in other studies, the O antigen is thought to be less determinant than the capsular antigens for resistance  
30 to serum (Russo T. et al., *Infect Immun*, 1995, Apr. 63(4):1263-9). Furthermore, the importance of these factors on intestinal colonization is unknown.

- 3 -

The inventors have carried out a systematic analysis of mutants for inactivation of the genes required for surface polysaccharide synthesis, and have demonstrated, in *Escherichia coli* strains responsible for extra-intestinal infections, EXPEC, which genes are essential for the resistance to serum and the dissemination in the blood. These results are based on the study of the effect of mutations on virulence and intestinal colonization in an animal model.

10 The invention is therefore directed towards a novel methodology for defining the targets required for virulence, and not essential *in vitro*, and thus providing novel anti-infectious agents specific for pathogenic bacteria, in particular for extra-intestinal *E.coli*, responsible for severe 15 infections, as well as Gram positive strains, such as *Streptococcus agalactiae*. It is also directed towards the products of the genes required for resistance in the serum and virulence *in vivo*.

20 The method of the invention for identifying and selecting a gene required for the proliferation *in vivo* of a pathogenic microorganism is characterized in that it comprises:

- using a strain of the pathogenic microorganism,
- generating mutants for inactivation in the genes encoding 25 the virulence factors,
- determining the virulence of these mutants on an experimental model of infection and their effect on enteric colonization in an axenic mouse model, and
- selecting the bacterial genes essential for resistance to 30 serum *in vitro* and essential, in the host, for dissemination in the blood.

- 4 -

The pathogenic microorganism is in particular an EXPEC strain of *E.coli* or a *Streptococcus agalactiae* strain.

5 The virulence gene inactivation mutants used in this method fall within the scope of the invention.

Said mutants are characterized by the following properties : they are sensitive to serum; they are avirulent in mice model and they are able to colonize gut of axenic mice.

10 The invention is also directed towards the pathogenicity or virulence factors encoded by nucleic acids thus identified, which are necessary for the dissemination via the blood, but do not significantly affect the intestinal or mucosal  
15 colonization of pathogenic bacteria such as *E.coli*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Yersinia pestis*, *Serratia marcescens*, *Haemophilus influenzae*, *Pasteurella multocida*, *Vibrio cholerae*, *Pseudomonas aeruginosa*, *Acetinobacter*, *Moraxella catarrhalis*, *Burkholderia pseudomallei*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Campylobacter jejuni*, *Helicobacter pylori*, *Bacteroides fragilis*, *Clostridium acetobutylicum*, *Mycobacterium tuberculosis*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Staphylococcus aureus* and *Enterococcus*.

25 The invention is in particular directed towards the pathogenicity or virulence targets encoded by isolated or purified nucleic acids having sequences SEQ ID Nos 16-30.

30 The pathogenicity or virulence targets of the invention are more particularly encoded by nucleic acids having sequences SEQ ID Nos 16,17,19-30.

Said nucleic acids are cDNAs or RNAs.

- 5 -

It particularly relates to pathogenicity or virulence targets encoded by nucleic acids of *E.coli*.

In another embodiment of the invention, the pathogenicity or virulence targets are encoded by nucleic acids of

5 *Streptococcus agalactiae*.

The invention is also directed towards the vectors comprising at least a nucleic acid coding for a pathogenicity or virulence target such as above defined and also the host cells

10 containing at least one vector under the control of a suitable promoter.

The invention is also directed towards pathogenicity or virulence factors corresponding to isolated or purified

15 polypeptides or peptides having one of the amino acid sequences SEQ ID Nos 1-15.

It more particularly relates to pathogenicity or virulence factors corresponding to isolated or purified polypeptides or

20 peptides having the amino acid sequences SEQ ID Nos 1,2,4-15.

The antibodies which are capable of binding specifically to the peptides and polypeptides corresponding to said factors are also part of the invention.

25

These nucleic acids and peptides or polypeptides constitute targets for identifying compounds with a specific inhibitory effect on the systemic dissemination of a bacterial infection, and not on mucosal colonization or, for enterobacteria, on 30 intestinal colonization, which makes it possible to preserve the commensal flora and to avoid the selection of resistance to the compounds.

- 6 -

The invention is thus directed towards the method for inhibiting the proliferation of a pathogenic microorganism in serum, comprising the use of an effective amount of a compound capable of inhibiting the activity, or of reducing the amount, 5 of a nucleic acid as defined above, or of a compound capable of inhibiting the activity of a polypeptide or of a peptide as defined above.

It is also directed towards a method for screening compounds 10 capable of inhibiting the expression of these nucleic acids or of the corresponding polypeptides and peptides, comprising bringing them into contact with the test compound, demonstrating the possible effect of the compound on their activity, and selecting the active compounds.

15 It is also directed towards a method for screening compounds capable of inhibiting the biochemical and/or enzyme activity of the polypeptides and peptides expressed by said nucleic acids.

20 The compounds thus selected are used, in accordance with the invention, to produce medicinal products for inhibiting a bacterial infection, in particular an extra-intestinal infection in the case of enterobacteria.

25 The invention thus provides a novel strategy and novel means for preventing or treating systemic bacterial dissemination, bacteraemia and septicaemia.

30 Other characteristics and advantages of the invention will be given in the following examples, with reference to Figures 1 to 3 and tables 1 to 5, said figures representing, respectively,

- 7 -

- Figure 1, the growth of S26 and of the mutant pg23 in serum,
- Figure 2, the growth of S26 and of the mutant pg23 in decomplemented serum, and
- 5 - Figure 3, the virulence of the DltD mutant of *S.agalactiae*.

Example 1 : gene corresponding to SEQ ID N°23:

1- Inactivation of the gene of interest

10 The general strategy, based on a recombination system, consists in interrupting a gene, by allelic recombination, with a gene for selection (a gene for resistance to antibiotic in the present case) carried by a linear DNA fragment.

15 Initially, a plasmid is introduced into the bacterium (for example *E.coli*), so as to introduce, in trans, the proteins which will induce the recombination. The plasmid carrying an ampicillin resistance gene is thermosensitive (30°C), which 20 will make it possible to easily eliminate it after use in the bacterium.

25 The plasmid is introduced into the bacterium by electroporation. After electroporation, the ampicillin-resistant bacteria will be those which have integrated the plasmid, and will be selected. This step is entirely carried out at 30°C, the permissive temperature for the plasmid.

Synthesis of the PCR fragment specific for the target gene (pg23)

30 A PCR is carried out, on a matrix plasmid carrying the selection gene (chloramphenicol resistance), using primers pg23P1 and pg23P2 of sequences SEQ ID No 31 and SEQ ID No 32, respectively, made up of two parts:

in 3': 20 bp homologous to the selection gene (chloramphenicol resistance): P1 or P2

in 5': 40 bp homologous to the target gene (pg23): H1 or H2

pg23P1:

TCGTGCAGGCCAACCTGCACAAACAGAGTGATTCGATTAACGTGTAGGCTGGAGCTGCTTC

3'

H1

P1

Pg23P2:

CAGGGTGCTGGCGCTCACCATTCGGAGACAGCTTAGACACATATGAATATCCTCCTTA

3'

H2

P2

5

A DNA fragment consisting of the selection gene (CAT: Chloramphenicol Acetyl Transferase) flanked by the regions homologous to the target gene H1 and H2 is thus obtained.

10 Step for inactivation of the target gene

The bacterium containing the plasmid is cultured in LB medium at 30°C with shaking, in the presence of 100 mM ampicillin and of 1 mM L-arabinose so as to induce the recombination system. When the bacteria are in the exponential growth phase 15 (OD<sub>600nm</sub>=0.5), the culture is stopped, and the bacteria are harvested and made electrocompetent. The PCR product specific for the target gene (pg23) is introduced into the bacterium by electroporation. The bacteria are then cultured in a non-selective rich medium (SOC medium) at 37°C with shaking for 20 hours, and then plated out onto selective LB agar medium. After 18 hours at 37°C, only the bacteria which have integrated the gene for resistance to the antibiotic will have grown.

25 Verification of the insertion of the resistance cassette

In order to verify the insertion of the resistance cassette, PCR reactions are carried out directly using colonies. Three

- 9 -

pairs of primers are used: a pair in which the primers FR1 and FR2 frame the target gene, and two pairs using a primer located inside the resistance cassette, the other primer being located either upstream or downstream of the target gene.

5

Isolation of the mutated bacteria and elimination of the plasmid

The colonies thus verified by PCR are successively re-isolated on selected medium, twice on non-selective medium and a final 10 time on selective medium at 37°C. Finally, the selected bacteria are tested for sensitivity to ampicillin, which reflects the absence of the plasmid. Three clones are thus chosen for each type of mutant.

15 2 - Test for the mutant with respect to resistance to the bactericidal activity of serum

The serum used is of human origin. In each experiment, growth was also effected for the wild-type strain (S26, clinical 20 isolate of *E.coli* particularly resistant to serum and virulent in mice) and a strain, ECOR4, lacking a capsule and lipopolysaccharide (LPS). The growths were effected in triplicate and in two different sera. The growths were effected in parallel in complemented and dekomplemented (30 25 min at 56°C) serum in order to verify that the effect observed was due only to the lytic action of complement.

Using a preculture of two hours in RPMI reference minimum medium, the bacteria are brought into contact with 100% serum, 30 at a starting inoculum of 10<sup>4</sup>cfu/ml. Counts are then performed at times 0, 1 and 4 hours, by plating various dilutions out on LB agar medium in the presence or absence of antibiotic. After 18 hours at 37°C, the bacteria are counted and a growth curve

- 10 -

is produced from the results obtained. These results are given in Figures 1 and 2.

5 In this example, the mutant  $\Delta$ pg23 exhibits considerable sensitivity to the serum: a difference from the wild-type strain of more than 2 log at 1 hour and of more than 4 log at 4 hours is in fact observed. In addition, the results obtained in decomplemented serum and with the strain ECOR4 in serum indicate that the effect observed is indeed due to the  
10 bactericidal action of complement.

### 3 - Study of the virulence in a mouse animal model

#### Preparation of the inoculum

15 The wild-type mutated bacteria are isolated from the strain, stored at  $-80^{\circ}\text{C}$ , on an LB agar dish with or without antibiotic, and incubated at  $37^{\circ}\text{C}$  for 18 hours. A preculture is prepared in liquid medium. Using a 1/10th dilution in 10 ml of LB, the culture is regrown at  $37^{\circ}\text{C}$  with shaking for 2  
20 hours. After culturing for 2 hours, the  $\text{OD}_{600\text{nm}}$  is measured and various dilutions are prepared in physiological saline, so as to obtain the desired inoculum. For the wild-type strain S26, the  $\text{LD}_{50}$  corresponds to an inoculum of  $5 \times 10^5$  cfu/mouse and the  $\text{LD}_{100}$  corresponds to an inoculum of  $1 \times 10^6$  cfu/mouse.

25

#### Virulence test

The mice (6-week-old Balb/c) are given an intraperitoneal injection and the bacterial solution injected represents a volume of 100  $\mu\text{l}$ . Five mice are used per dose. For S26 $\Delta$ pg23, 4  
30 inoculums were tested and the survival rate was measured after 24 and 48 hours post-injection. In each experiment, the study was carried out in parallel with the wild-type strain, the  $\text{LD}_{50}$  of which is  $5 \times 10^5$  cfu/mouse.

The mutant S26 $\Delta$ pg23, injected at a dose equal to 10 times the LD<sub>100</sub>, causes no mortality, the mutation of the pg23 gene in the *E.coli* strain K1 S26 is therefore responsible for a 5 considerable decrease in the virulence.

4 - Study of the intestinal colonization in an axenic mouse animal model

10 The entire experiment is carried out in a sterile environment, with sterile instruments, in an isolator, and the mice are given sterile food.

Mice

15 These are 6- to 8-week-old axenic female mice of the C3H/He J line.

Four animals are used per bacterial strain.

20 Preparation of the inoculum

The wild-type and mutated bacteria are isolated from the strain, stored at -80°C, on an LB agar dish with or without antibiotic, and incubated at 37°C for 18 hours. After culturing the strain in liquid medium, various dilutions are 25 prepared in physiological saline, so as to obtain an inoculum of 10<sup>7</sup> cfu/ml.

Colonization test

The bacterial inoculation is carried out orally. During the 24 30 hours preceding inoculation, the mice are deprived of water. They are then given a bacterial solution at 10<sup>7</sup> cfu/ml to drink for 4 hours. The volume of drink is measured at 0 and 4 hours, and, on average, a mouse absorbs 5 ml of this bacterial solution. The faeces are then sampled at various times, and a

- 12 -

bacterial count is performed, taking the faeces up in physiological saline and plating out various dilutions on an LB agar dish with and without antibiotic.

The results are given in table 1 herein below.

5

TABLE 1

Time in hours	CFU/mg faeces	
	S26wt	S26 $\Delta$ pg23
0	0	0
4	6.85E+05	1.65E+05
25	1.86E+06	2.84E+06
118	8.34E+06	7.94E+06
456	4.14E+06	6.64E+06

For the wild-type strain S26, as well as for the mutant S26 $\Delta$ pg23, colonization in the intestine was stably 10 established. No difference is observed between the wild-type strain and the mutant  $\Delta$ pg23. The colonization is confirmed on the final day by removing the intestine and counting the bacteria after grinding of this organ.

15 5 - Cloning and expression of the selected polypeptide

The nucleic acid encoding the polypeptide is cloned into a prokaryotic expression vector such as pET-14b with an N-terminal poly-his tag, according to conventional cloning 20 methods.

The recombinant plasmid is then used to transform the *E.coli* strain BL21. The transformed cells are selected in the presence of ampicillin and the colonies are isolated. They are 25 then cultured in the presence of IPTG in order to induce expression of the protein. The clones producing the protein

- 13 -

are cultured and the total proteins are extracted by cell lysis. The recombinant protein is purified with a histidine tag affinity column, according to the manufacturer's protocol.

5 The protein thus obtained is purified and used *in vitro* to measure its enzyme activity.

Example 2 : serum sensitivity and LD<sub>50</sub> determination of mutant strains in the mice model of infection

10 Said mutants were also compared to the wild type S26 *E.coli* strain for LD<sub>50</sub> determination in the mice model of infection. As presented in Table 2 below, the number of colony forming unit (cfu) counted after culture for four hours in serum was 15 higher in the wild type (wt) S26 strain than in mutants indicating that mutants were sensitive to serum killing. All the different mutants were either much less virulent in mice than the wild type strain as shown by the increase in LD<sub>50</sub> (lethal dose 50), or completely avirulent as no dose killing 20 50% of mice could be reach with the mutants.

Table 2

5 Serum sensitivity and virulence attenuation for *E. coli* K1 S26 mutants in the proteins corresponding to sequence number 1 to 13

Sequence Number	Serum sensitivity # Δlog (cfu/ml serum)	Virulence attenuation * Δlog (LD <sub>50</sub> )
1	+4	avirulent <sup>a</sup>
2	+4	+1
3	+5	+1
4	+4	+1
5	+4	+2,5
6	+4	+0,5
7	+4	+0,5
8	+4	avirulent <sup>a</sup>
9	+1	avirulent <sup>a</sup>
10	+2	avirulent <sup>a</sup>
11	+4	+2
12	+4	+2
13	+4	avirulent <sup>a</sup>

avirulent<sup>a</sup>: no dose killing 50% of mice could be reach with that mutant.

10 # Δlog (cfu/ml serum) = log (cfu S26wt / ml serum) - log (cfu S26 mutant / ml serum)

values obtained after 4 hours in serum

\* Δlog (LD<sub>50</sub>) = log (LD<sub>50</sub> S26mutant) - log (LD<sub>50</sub> S26wt)

values obtained 48 hours after inoculation

15 The mutants of genes encoding the target proteins corresponding to sequences 1 to 13, which were attenuated for virulence, were still able to colonize the intestine of axenic mice as shown by persistence of bacteria in the faeces of the

- 15 -

animals over a period of eight days. These results are presented in Table 3.

Table 3

5

Gut colonization for *E. coli* K1 S26 wt and mutants in the proteins corresponding to sequence number 1 to 13 in an axenic mouse model

Sequence number	Gut colonization	
	cfu/mg faeces	
	Day 1	Day 8
S26 wt	* 1,34.10 <sup>6</sup>	* 5,29.10 <sup>6</sup>
S26 mutants	1	9,73.10 <sup>5</sup>
	2	1,02.10 <sup>6</sup>
	3	1,44.10 <sup>6</sup>
	4	1,24.10 <sup>6</sup>
	5	1,15.10 <sup>5</sup>
	6	9,96.10 <sup>5</sup>
	7	2,40.10 <sup>4</sup>
	8	2,84.10 <sup>6</sup>
	9	1,80.10 <sup>6</sup>
	10	9,62.10 <sup>5</sup>
	11	2,72.10 <sup>5</sup>
	12	3,13.10 <sup>5</sup>
	13	5,91.10 <sup>5</sup>

\* mean values based upon six experiments

10 The bacteria colonizing the intestine of axenic mice after eight days were characterized to verify that they correspond to the mutant strains that were inoculated orally.

15 The bacteria recovered from the faeces of animals had a phenotype of chloramphenicol resistance and serum sensitivity, the chloramphenicol acetyl transferase gene inserted during the mutagenesis could also be detected by PCR.

- 16 -

Mutations in genes encoding target proteins (sequence number 1 to 13) were still present in bacteria colonizing the intestine of axenic mice as shown in Table 4.

5

Table 4

Characterization of bacteria recovered from axenic mice after intestinal colonization by mutants in genes encoding proteins sequence 1 to 13

10

Sequence Number	Serum sensitivity # ΔLog (cfu/ml serum)	* Mutant genotype
1	+5	Cm <sup>R</sup> , PCR +
2	+4	Cm <sup>R</sup>
3	+5	Cm <sup>R</sup>
4	+3	Cm <sup>R</sup>
5	+5	Cm <sup>R</sup> , PCR +
6	+2	Cm <sup>R</sup>
7	+2	Cm <sup>R</sup>
8	Nd	Cm <sup>R</sup>
9	+2	Cm <sup>R</sup>
10	+3	Cm <sup>R</sup>
11	+5	Cm <sup>R</sup> , PCR +
12	+4	Cm <sup>R</sup> , PCR +
13	+4	Cm <sup>R</sup> , PCR +

# ΔLog (cfu/ml serum) = log (cfu S26wt / ml serum) - log (cfu S26mutant / ml serum)

values obtained after 4 hours in serum

\*The presence of the gene encoding the chloramphenicol acetyltransferase, inactivating the genes encoding the proteins of sequence number 1 to 13, has been verified by PCR and chloramphenicol resistance (Cm<sup>R</sup>).

In conclusion, the results presented in this example demonstrate that genes encoding the enzymes involved in the LPS inner core metabolism are not essential in *E.coli* strains

- 17 -

for colonization, but are necessary for resistance to complement and virulence *in vivo*.

They represent as such good targets for inhibitors that will 5 selectively block bacterial replication in blood tissue.

Example 2: mutants of protein SEQ ID N°14

The present invention relates to novel mutant strain of Group 10 B *Streptococcus* (GBS) (*Streptococcus agalactiae*). In this particular example, the identified targets correspond to gene sequence number 29 encoding a protein sequence number 14 involved in incorporation of D-alanine residues into the cell wall-associated lipoteichoic acids (LTAs) in Gram + bacteria.

15 The gene sequence number 29 is homologous to the *dltD* gene found in other gram positive bacteria and is the last gene of the *dlt* operon.

20 The Gram + bacterial model used is the pathogenic strain *S. agalactiae* NEM316. *S. agalactiae* is a bacterium commonly found in the human flora and is phylogenetically close to Gram + bacteria responsible for nosocomial septicemia.

25 The virulence of GBS mutants in the *dlt* operon is strongly impaired in mouse and newborn rat models.

30 Interestingly, the loss of virulence is presumably due to an increased sensitivity to antimicrobial cationic peptides, such as defensins, which are produced by numerous cell types in particular phagocytes.

35 The use of mutant of *S. agalactiae*, in which the *dltD* gene have been inactivated, demonstrates that the product of that gene is a good target for the development of inhibitors of virulence of *S. agalactiae* as well as against other Gram + pathogens.

Construction of a DltD mutant in wild type *S. agalactiae* NEM316:

5 A mutant in the *dltD* gene was constructed from *S. agalactiae* NEM316 strain by inserting, using double cross-over, a kanamycin resistance cassette.

10 To construct *DltD* mutant of *S. agalactiae* NEM316, a promoterless and terminatorless kanamycin resistance cassette *aphA-3* within DNA segment internal to *dltD* were inserted in the same direction of transcription. This was done by ligation after digestion with appropriate enzymes, of PCR products obtained by using the primers of SEQ ID N° 33 and 34 respectively,

15

SEQ ID N°33 : 5'-CAGTGAATTGCGCTTGACGAAGGCAGG-3', and  
SEQ ID N°34 : 5'-GACGGGTACCATACCTATCGTAGGTTG-3', and  
the primers of SEQ ID N° 35 and SEQ ID N°36, respectively,  
SEQ ID N°35 : 5'-AGTGGATCCACTACACAGGGCTTGATC-3', and  
20 SEQ ID N°36 : 5'-GACCTGCAGCCCTTGATTATCCCTATCC-3'.

25 A 0.4 kb *dltD* EcoRI-KpnI fragment was inserted into the thermosensitive shuttle vector pG+host5ΩaphA-3 (Biswas et al., 1993, J Bacteriol. 175:3628-3635) containing the kanamycin resistance cassette to generate pG1Ω EKaphA-3. A 0.8 kb closely spaced *dltD* region BamHI-PstI fragment was inserted into pG1Ω EKaphA-3 to generate pG1Ω EKaphA-3BP. The resulting vector was introduced by electroporation into NEM316. Transformants were selected on Todd-Hewitt (TH) agar plates 30 containing 10 mg l<sup>-1</sup> erythromycin at 30°C. Allelic exchange was obtained at the non-permissive temperature (42°C) by homologous recombination using a two-step procedure described previously (Biswas et al., 1993).

35 A double-crossover event between the homologous sequences resulted in nucleotides deletion and insertion of the kanamycine cassette. Recombinant bacteria containing this insertion deletion were selected for kanamycine resistance.

- 19 -

This chromosome disruption in the *dltD* gene was confirmed in one of the recombinant clones by sequencing the nucleotides of the mutant.

5 Sensitivity of the wild type *S. agalactiae* strain NEM316 and the *DltD* mutant to various antimicrobial peptides :

The sensitivity of wild type *S. agalactiae* NEM316 and *DltD* mutant to cationic antimicrobial peptides was measured by 10 using a disk diffusion methods. The 2 strains were grown on blood agar plates and incubated for 18 hours at 37°C. Each strain was tested using colistin (50 µg) and polymixin (10 µg) 15 disks. Sensitivity or resistance of NEM316 strain and the *DltD* mutant to each compound was determined by the size of the growth inhibition area around disk.

The *DltD* mutant exhibited an increased sensitivity to the cationic antimicrobial peptides colistin, and polymyxin B as shown in table 5.

20

Table 5

Results of sensitivity to colistin and polymixin B of control strains *S. agalactiae* NEM316 and *DltD* mutant

25

	Disc content (µg)	Inhibition area (mm)	
		NEM316	Mutant <i>DltD</i>
Colistin	50	0	14
Polymixin B	10	0	14

Study of virulence in a mouse animal model

We studied the role of *DltD* in the virulence of *S. agalactiae*.

30 Groups of ten mice (six week-old Balb/c) were inoculated intravenously with  $5 \times 10^7$  bacteria. At 2 days post infection, 80% of mice infected with the wild type strain NEM316 died and

- 20 -

only two deaths were recorded for mice infected with the DltD mutant. Figure 1 illustrates the results obtained with the DltD defective GBS mutant. The result demonstrates that the product of the dltD gene is necessary for virulence of GBS in  
5 mice.

- 21 -

**CLAIMS**

1. Method for identifying and selecting a gene required for the proliferation *in vivo* of a pathogenic microorganism, comprising :

- using a strain of the pathogenic microorganism,
- generating mutants for inactivation in the genes encoding these factors,
- determining the virulence of these mutants on an experimental model of infection, and their effect on enteric colonization in an axenic mouse model, and
- selecting the bacterial genes essential for resistance to serum *in vitro*, and essential, in the host, for dissemination in the serum.

2. Method according to Claim 1, characterized by the use of an *E.coli* strain EXPEC or a *Streptococcus agalactiae* strain.

3. Mutant nucleic acids for inactivation of the virulence genes as implemented in the method according to Claim 1 or 2.

4. Mutant nucleic acids which are sensitive to serum; avirulent in mice model and able to colonize gut of axenic mice.

5. Pathogenicity or virulence targets encoded by isolated or purified nucleic acids corresponding to one of the nucleotide sequences SEQ ID Nos 16-30.

6. Pathogenicity or virulence targets according to claim 5, wherein said nucleic acids correspond to one of the nucleotide sequences SEQ ID Nos 16,17,19-30.

- 22 -

7. Pathogenicity or virulence targets according to claim 5 or 6, wherein said nucleic acids are cDNAs.

8. Pathogenicity or virulence targets according to claim 5 or 6, wherein said nucleic acids are RNAs.

9. Pathogenicity or virulence targets according to any one of claims 6 to 8, wherein said nucleic acids correspond to the nucleic acids of pathogenic organisms comprising  
10 *Escherichia coli*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Yersinia pestis*, *Serratia marcescens*, *Haemophilus influenzae*, *Pasteurella multocida*, *Vibrio cholerae*, *Pseudomonas aeruginosa*, *Acetinobacter*, *Moraxella catarrhalis*, *Burkholderia pseudomallei*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Campylobacter jejuni*, *Helicobacter pylori*, *Bacteroides fragilis*, *Clostridium acetobutylicum*, *Mycobacterium tuberculosis*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Staphylococcus aureus* and *Enterococcus*.

20  
10. Pathogenicity or virulence targets according to claim 9 corresponding to nucleic acids of *E.coli* or *Streptococcus agalactiae*.

25 11. Vectors comprising at least one pathogenicity or virulence target according to any one of claims 5 to 10.

12. Host cells containing at least one vector according to Claim 11.

30  
13. Products of expression of the pathogenicity or virulence targets according to any one of claims 5 to 10.

- 23 -

14. Isolated or purified peptides characterized in that they correspond to one of the amino acid sequences SEQ ID Nos. 1 to 15.

5 15. Isolated or purified peptides according to claim 14 characterized in that they correspond to one of the amino acid sequences SEQ ID Nos 1,2,4-15.

10 16. Antibodies capable of binding specifically to the peptides according to any one of Claims 13 to 15.

15 17. Method for inhibiting *in vitro* the proliferation of a pathogenic microorganism in serum, comprising the use of an effective amount of a compound capable of inhibiting the activity, or of reducing the amount, of pathogenicity or virulence target according to any one of claims 6 to 10, or of inhibiting the activity of a peptide according to Claim 15.

20 18. Method for screening compounds capable of inhibiting the expression of the pathogenicity or virulence target according to any one of claims 6 to 10, or peptides according to claim 15, comprising bringing into contact with the test compound, demonstrating the possible effect of the compound on their activity, and selecting the active compounds.

25 19. Method for screening compounds capable of inhibiting the biochemical and/or enzyme activity of the peptides expressed by the pathogenicity or virulence target according to any one of claims 6 to 10.

30 20. Use of the compounds selected according to Claim 19, for developing medicinal products for inhibiting a bacterial infection, in particular an extra-intestinal infection in the case of enterobacteria.

1/2

FIGURE 1






FIGURE 2

2/2

**FIGURE 3**

## SEQUENCE LISTING

&lt;110&gt; MUTABILIS S.A.

&lt;120&gt; Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination

&lt;130&gt; 1621

&lt;160&gt; 32

&lt;170&gt; PatentIn version 3.1

&lt;210&gt; 1

&lt;211&gt; 305

&lt;212&gt; PRT

&lt;213&gt; Escherichia coli

&lt;400&gt; 1

Pro Ala Leu Thr Asp Ala Gln Gln Ala Ile Pro Gly Ile Lys Phe Asp  
1 5 10 15Trp Val Val Glu Glu Gly Phe Ala Gln Ile Pro Ser Trp His Ala Ala  
20 25 30Val Glu Arg Val Ile Pro Val Ala Ile Arg Arg Trp Arg Lys Ala Trp  
35 40 45Phe Ser Ala Pro Ile Lys Ala Glu Arg Lys Ala Phe Arg Glu Ala Leu  
50 55 60Gln Ala Glu Asn Tyr Asp Ala Val Ile Asp Ala Gln Gly Leu Val Lys  
65 70 75 80Ser Ala Ala Leu Val Thr Arg Leu Ala His Gly Val Lys His Gly Leu  
85 90 95Asp Trp Gln Thr Ala Arg Glu Pro Leu Ala Ser Leu Phe Tyr Asn Cys  
100 105 110Lys His His Ile Ala Lys Gln Gln His Ala Val Glu Arg Thr Arg Glu  
115 120 125Leu Phe Ala Lys Ser Leu Gly Tyr Ser Lys Pro Gln Thr Gln Gly Asp  
130 135 140Tyr Ala Ile Ala Gln His Phe Leu Thr Asn Leu Pro Thr Asp Ala Gly  
145 150 155 160Glu Tyr Ala Val Phe Leu His Ala Thr Thr Arg Asp Asp Lys His Trp  
165 170 175Pro Glu Glu His Trp Arg Glu Leu Ile Gly Leu Leu Ala Asp Ser Gly  
180 185 190

Ile Arg Ile Lys Leu Pro Trp Gly Ala Pro His Glu Glu Arg Ala

Lys Arg Leu Ala Glu Gly Phe Ala Tyr Val Glu Val Leu Pro Lys Met  
210 215 220

Ser Leu Glu Gly Val Ala Arg Val Leu Ala Gly Ala Lys Phe Val Val  
225 230 235 240

Ser Val Asp Thr Gly Leu Ser His Leu Thr Ala Ala Leu Asp Arg Pro  
245 250 255

Asn Ile Thr Val Tyr Gly Pro Thr Asp Pro Gly Leu Ile Gly Gly Tyr  
260 265 270

Gly Lys Asn Gln Met Val Cys Arg Ala Pro Gly Asn Glu Leu Ser Gln  
275 280 285

Leu Thr Ala Asn Ala Val Lys Arg Phe Ile Glu Glu Asn Ala Ala Met  
290 295 300

Ile  
305

<210> 2  
<211> 340  
<212> PRT  
<213> Escherichia coli  
<400> 2

Met Arg Phe His Gly Asp Met Leu Leu Thr Thr Pro Val Ile Ser Ser  
1 5 10 15

Leu Lys Lys Asn Tyr Pro Asp Ala Lys Ile Asp Val Leu Leu Tyr Gln  
20 25 30

Asp Thr Ile Pro Ile Leu Ser Glu Asn Pro Glu Ile Asn Ala Leu Tyr  
35 40 45

Gly Ile Lys Asn Lys Lys Ala Lys Ala Ser Glu Lys Ile Ala Asn Phe  
50 55 60

Phe His Leu Ile Lys Val Leu Arg Ala Asn Lys Tyr Asp Leu Ile Val  
65 70 75 80

Asn Leu Thr Asp Gln Trp Met Val Ala Ile Leu Val Arg Leu Leu Asn  
85 90 95

Ala Arg Val Lys Ile Ser Gln Asp Tyr His His Arg Gln Ser Ala Phe  
100 105 110

Trp Arg Lys Ser Phe Thr His Leu Val Pro Leu Gln Gly Gly Asn Val  
115 120 125

Val Glu Ser Asn Leu Ser Val Leu Thr Pro Leu Gly Val Asp Ser Leu  
130 135 140

Val Lys Gln Thr Thr Met Ser Tyr Pro Pro Ala Ser Trp Lys Arg Met  
145 150 155 160

Arg Arg Glu Leu Asp His Ala Gly Val Gly Gln Asn Tyr Val Val Ile  
165 170 175

Gln Pro Thr Ala Arg Gln Ile Phe Lys Cys Trp Asp Asn Ala Lys Phe  
180 185 190

Ser Ala Val Ile Asp Ala Leu His Ala Arg Gly Tyr Glu Val Val Leu  
195 200 205

Thr Ser Gly Pro Asp Lys Asp Asp Leu Ala Cys Val Asn Glu Ile Ala  
210 215 220

Gln Gly Cys Gln Thr Pro Pro Val Thr Ala Leu Ala Gly Lys Val Thr  
225 230 235 240

Phe Pro Glu Leu Gly Ala Leu Ile Asp His Ala Gln Leu Phe Ile Gly  
245 250 255

Val Asp Ser Ala Pro Ala His Ile Ala Ala Val Asn Thr Pro Leu  
260 265 270

Ile Ser Leu Phe Gly Ala Thr Asp His Ile Phe Trp Arg Pro Trp Ser  
275 280 285

Asn Asn Met Ile Gln Phe Trp Ala Gly Asp Tyr Arg Glu Met Pro Thr  
290 295 300

Arg Asp Gln Arg Asp Arg Asn Glu Met Tyr Leu Ser Val Ile Pro Ala  
305 310 315 320

Ala Asp Val Ile Ala Ala Val Asp Lys Leu Leu Pro Ser Ser Thr Thr  
325 330 335

Gly Thr Ser Leu  
340

<210> 3  
<211> 265  
<212> PRT  
<213> Escherichia coli  
<400> 3

Met Val Glu Leu Lys Glu Pro Phe Ala Thr Leu Trp Arg Gly Lys Asp  
1 5 10 15

Pro Phe Glu Glu Val Lys Thr Leu Gln Gly Glu Val Phe Arg Glu Leu  
20 25 30

Glu Thr Arg Arg Thr Leu Arg Phe Glu Met Ala Gly Lys Ser Tyr Phe  
35 40 45

Leu Lys Trp His Arg Gly Thr Thr Leu Lys Glu Ile Ile Lys Asn Leu  
50 55 60

Leu Ser Leu Arg Met Pro Val Leu Gly Ala Asp Arg Glu Trp Asn Ala  
65 70 75 80

Ile His Arg Leu Arg Asp Val Gly Val Asp Thr Met Tyr Gly Val Ala  
85 90 95

Phe Gly Glu Lys Gly Met Asn Pro Leu Thr Arg Thr Ser Phe Ile Ile  
100 105 110

Thr Glu Asp Leu Thr Pro Thr Ile Ser Leu Glu Asp Tyr Cys Ala Asp  
115 120 125

Trp Ala Thr Asn Pro Pro Asp Val Arg Val Lys Arg Met Leu Ile Lys  
130 135 140

Arg Val Ala Thr Met Val Arg Asp Met His Ala Ala Gly Ile Asn His  
145 150 155 160

Arg Asp Cys Tyr Ile Cys His Phe Leu Leu His Leu Pro Phe Ser Gly  
165 170 175

Lys Glu Glu Glu Leu Lys Ile Ser Val Ile Asp Leu His Arg Ala Gln  
180 185 190

Leu Arg Thr Arg Val Pro Arg Arg Trp Arg Asp Lys Asp Leu Ile Gly  
195 200 205

Leu Tyr Phe Ser Ser Met Asn Ile Gly Leu Thr Gln Arg Asp Ile Trp  
210 215 220

Arg Phe Met Lys Val Tyr Phe Ala Ala Pro Leu Lys Asp Ile Leu Lys  
225 230 235 240

Gln Glu Gln Gly Leu Leu Ser Gln Ala Glu Ala Lys Ala Thr Lys Ile  
245 250 255

Arg Glu Arg Thr Ile Arg Lys Ser Leu  
260 265

<211> 374  
<212> PRT  
<213> Escherichia coli  
<400> 4

Met Ile Val Ala Phe Cys Leu Tyr Lys Tyr Phe Pro Phe Gly Gly Leu  
1 5 10 15

Gln Arg Asp Phe Met Arg Ile Ala Gln Thr Val Ala Ala Arg Gly His  
20 25 30

His Val Arg Val Tyr Thr Gln Ser Trp Glu Gly Glu Cys Pro Asp Val  
35 40 45

Phe Glu Leu Ile Lys Val Pro Val Lys Ser His Thr Asn His Gly Arg  
50 55 60

Asn Ala Glu Tyr Phe Ala Trp Val Gln Lys His Leu Arg Glu His Pro  
65 70 75 80

Val Asp Lys Val Val Gly Phe Asn Lys Met Pro Gly Leu Asp Val Tyr  
85 90 95

Tyr Ala Ala Asp Val Cys Tyr Ala Glu Lys Val Ala Gln Glu Lys Gly  
100 105 110

Phe Phe Tyr Arg Leu Thr Ser Arg Tyr Arg His Tyr Ala Ala Phe Glu  
115 120 125

Arg Ala Thr Phe Glu Gln Gly Lys Pro Thr Gln Leu Leu Met Leu Thr  
130 135 140

Asp Lys Gln Ile Ala Asp Phe Gln Lys His Tyr Gln Thr Glu Ala Glu  
145 150 155 160

Arg Phe His Ile Leu Pro Pro Gly Ile Tyr Pro Asp Arg Lys Tyr Ser  
165 170 175

Gln Gln Pro Ala Asn Ser Arg Glu Ile Phe Arg Lys Lys Asn Gly Ile  
180 185 190

Thr Glu Gln Gln Tyr Leu Leu Gln Val Gly Ser Asp Phe Thr Arg  
195 200 205

Lys Gly Val Asp Arg Ser Ile Glu Ala Leu Ala Ser Leu Pro Asp Ser  
210 215 220

Leu Arg His Asn Thr Leu Leu Tyr Val Val Gly Gln Asp Lys Pro Arg  
225 230 235 240

Lys Phe Glu Ala Leu Ala Glu Lys Arg Gly Val Arg Ser Asn Val His

245

250

255

Phe Phe Ser Gly Arg Asn Asp Val Ser Glu Leu Met Ala Ala Ala Asp  
260 265 270

Leu Leu Leu His Pro Ala Tyr Gln Glu Ala Ala Gly Ile Val Leu Leu  
275 280 285

Glu Ala Ile Thr Ala Gly Leu Pro Val Leu Thr Thr Ala Val Cys Gly  
290 295 300

Tyr Ala His Tyr Ile Val Asp Ala Asn Cys Gly Glu Ala Ile Ala Glu  
305 310 315 320

Pro Phe Arg Gln Glu Thr Leu Asn Glu Ile Leu Arg Lys Ala Leu Thr  
325 330 335

Gln Ser Ser Leu Arg Gln Ala Trp Ala Glu Asn Ala Arg His Tyr Ala  
340 345 350

Asp Thr Gln Asp Leu Tyr Ser Leu Pro Glu Lys Ala Ala Asp Ile Ile  
355 360 365

Thr Gly Gly Leu Asp Gly  
370

<210> 5  
<211> 348  
<212> PRT  
<213> Escherichia coli  
<400> 5

Met Lys Ile Leu Val Ile Gly Pro Ser Trp Val Gly Asp Met Met Met  
1 5 10 15

Ser Gln Ser Leu Tyr Arg Thr Leu Gln Ala Arg Tyr Pro Gln Ala Ile  
20 25 30

Ile Asp Val Met Ala Pro Ala Trp Cys Arg Pro Leu Leu Ser Arg Met  
35 40 45

Pro Glu Val Asn Glu Ala Ile Pro Met Pro Leu Gly His Gly Ala Leu  
50 55 60

Glu Ile Gly Glu Arg Arg Lys Leu Gly His Ser Leu Arg Glu Lys Arg  
65 70 75 80

Tyr Asp Arg Ala Tyr Val Leu Pro Asn Ser Phe Lys Ser Ala Leu Val  
85 90 95

Pro Phe Phe Ala Gly Ile Pro His Arg Thr Gly Trp Arg Gly Glu Met

100

105

110

Arg Tyr Gly Leu Leu Asn Asp Val Arg Val Leu Asp Lys Glu Ala Trp  
115 120 125

Pro Leu Met Val Glu Arg Tyr Ile Ala Leu Ala Tyr Asp Lys Gly Ile  
130 135 140

Met Arg Thr Ala Gln Asp Leu Pro Gln Pro Leu Leu Trp Pro Gln Leu  
145 150 155 160

Gln Val Ser Glu Gly Glu Lys Ser Tyr Thr Cys Asn Gln Phe Ser Leu  
165 170 175

Ser Ser Glu Arg Pro Met Ile Gly Phe Cys Pro Gly Ala Glu Phe Gly  
180 185 190

Pro Ala Lys Arg Trp Pro His Tyr His Tyr Ala Glu Leu Ala Lys Gln  
195 200 205

Leu Ile Asp Glu Gly Tyr Gln Val Val Leu Phe Gly Ser Ala Lys Asp  
210 215 220

His Glu Ala Gly Asn Glu Ile Leu Ala Ala Leu Asn Thr Glu Gln Gln  
225 230 235 240

Ala Trp Cys Arg Asn Leu Ala Gly Glu Thr Gln Leu Asp Gln Ala Val  
245 250 255

Ile Leu Ile Ala Ala Cys Lys Ala Ile Val Thr Asn Asp Ser Gly Leu  
260 265 270

Met His Val Ala Ala Leu Asn Arg Pro Leu Val Ala Leu Tyr Gly  
275 280 285

Pro Ser Ser Pro Asp Phe Thr Pro Pro Leu Ser His Lys Ala Arg Val  
290 295 300

Ile Arg Leu Ile Thr Gly Tyr His Lys Val Arg Lys Gly Asp Ala Ala  
305 310 315 320

Glu Gly Tyr His Gln Ser Leu Ile Asp Ile Thr Pro Gln Arg Val Leu  
325 330 335

Glu Glu Leu Asn Ala Leu Leu Glu Glu Ala  
340 345

<213> Escherichia coli  
<400> 6

Met Ser Ala His Tyr Phe Asn Pro Gln Glu Met Ile Asn Lys Thr Ile  
1 5 10 15

Ile Phe Asp Glu Arg Pro Ala Ala Ser Val Ala Ser Ser Phe His Val  
20 25 30

Ala Tyr Gly Ile Asp Lys Asn Phe Leu Phe Gly Cys Gly Val Ser Ile  
35 40 45

Thr Ser Val Leu Leu His Asn Asn Asp Val Ser Phe Val Phe His Val  
50 55 60

Phe Ile Asp Asp Ile Pro Glu Ala Asp Ile Gln Arg Leu Ala Gln Leu  
65 70 75 80

Ala Lys Ser Tyr Arg Thr Cys Ile Gln Ile His Leu Val Asn Cys Glu  
85 90 95

Arg Leu Lys Ala Leu Pro Thr Thr Lys Asn Trp Ser Ile Ala Met Tyr  
100 105 110

Phe Arg Phe Val Ile Ala Asp Tyr Phe Ile Asp Gln Gln Asp Lys Ile  
115 120 125

Leu Tyr Leu Asp Ala Asp Ile Ala Cys Gln Gly Asn Leu Lys Pro Leu  
130 135 140

Ile Thr Met Asp Leu Ala Asn Asn Val Ala Ala Val Val Thr Glu Arg  
145 150 155 160

Asp Ala Asn Trp Trp Ser Leu Arg Gly Gln Ser Leu Gln Cys Asn Glu  
165 170 175

Leu Glu Lys Gly Tyr Phe Asn Ser Gly Val Leu Leu Ile Asn Thr Leu  
180 185 190

Ala Trp Ala Gln Glu Ser Val Ser Ala Lys Ala Met Ser Met Leu Ala  
195 200 205

Asp Lys Ala Ile Val Ser Arg Leu Thr Tyr Met Asp Gln Asp Ile Leu  
210 215 220

Asn Leu Ile Leu Leu Gly Lys Val Lys Phe Ile Asp Ala Lys Tyr Asn  
225 230 235 240

Thr Gln Phe Ser Leu Asn Tyr Glu Leu Lys Lys Ser Phe Val Cys Pro  
245 250 255

Ile Asn Asp Glu Thr Val Leu Ile His Tyr Val Gly Pro Thr Lys Pro  
260 265 270

Trp His Tyr Trp Ala Gly Tyr Pro Ser Ala Gln Pro Phe Ile Lys Ala  
275 280 285

Lys Glu Ala Ser Pro Trp Lys Asn Glu Pro Leu Met Arg Pro Val Asn  
290 295 300

Ser Asn Tyr Ala Arg Tyr Cys Ala Lys His Asn Phe Lys Gln Asn Lys  
305 310 315 320

Pro Ile Asn Gly Ile Met Asn Tyr Ile Tyr Tyr Phe Tyr Leu Lys Ile  
325 330 335

Ile Lys

<210> 7  
<211> 302  
<212> PRT  
<213> Escherichia coli  
<400> 7

Met Ala Ala Ile Asn Thr Lys Val Lys Lys Ala Val Ile Pro Val Ala  
1 5 10 15

Gly Leu Gly Thr Arg Met Leu Pro Ala Thr Lys Ala Ile Pro Lys Glu  
20 25 30

Met Leu Pro Leu Val Asp Lys Pro Leu Ile Gln Tyr Val Val Asn Glu  
35 40 45

Cys Ile Ala Ala Gly Ile Thr Glu Ile Val Leu Val Thr His Ser Ser  
50 55 60

Lys Asn Ser Ile Glu Asn His Phe Asp Thr Ser Phe Glu Leu Glu Ala  
65 70 75 80

Met Leu Glu Lys Arg Val Lys Arg Gln Leu Leu Asp Glu Val Gln Ser  
85 90 95

Ile Cys Pro Pro His Val Thr Ile Met Gln Val Arg Gln Gly Leu Ala  
100 105 110

Lys Gly Leu Gly His Ala Val Leu Cys Ala His Pro Val Val Gly Asp  
115 120 125

Glu Pro Val Ala Val Ile Leu Pro Asp Val Ile Leu Asp Glu Tyr Glu  
130 135 140

Ser Asp Leu Ser Gln Asp Asn Leu Ala Glu Met Ile Arg Arg Phe Asp  
145 150 155 160

Glu Thr Gly His Ser Gln Ile Met Val Glu Pro Val Ala Asp Val Thr  
165 170 175

Ala Tyr Gly Val Val Asp Cys Lys Gly Val Glu Leu Ala Pro Gly Glu  
180 185 190

Ser Val Pro Met Val Gly Val Val Glu Lys Pro Lys Ala Asp Val Ala  
195 200 205

Pro Ser Asn Leu Ala Ile Val Gly Arg Tyr Val Leu Ser Ala Asp Ile  
210 215 220

Trp Pro Leu Leu Ala Lys Thr Pro Pro Gly Ala Gly Asp Glu Ile Gln  
225 230 235 240

Leu Thr Asp Ala Ile Asp Met Leu Ile Glu Lys Glu Thr Val Glu Ala  
245 250 255

Tyr His Met Lys Gly Lys Ser His Asp Cys Gly Asn Lys Leu Gly Tyr  
260 265 270

Met Gln Ala Phe Val Glu Tyr Gly Ile Arg His Asn Thr Leu Gly Thr  
275 280 285

Glu Phe Lys Ala Trp Leu Glu Glu Met Gly Ile Lys Lys  
290 295 300

<210> 8  
<211> 546  
<212> PRT  
<213> Escherichia coli  
<400> 8

Met Ala Ile His Asn Arg Ala Gly Gln Pro Ala Gln Gln Ser Asp Leu  
1 5 10 15

Ile Asn Val Ala Gln Leu Thr Ala Gln Tyr Tyr Val Leu Lys Pro Glu  
20 25 30

Ala Gly Asn Ala Glu His Ala Val Lys Phe Gly Thr Ser Gly His Arg  
35 40 45

Gly Ser Ala Ala Arg His Ser Phe Asn Glu Pro His Ile Leu Ala Ile  
50 55 60

Ala Gln Ala Ile Ala Glu Glu Arg Ala Lys Asn Gly Ile Thr Gly Pro  
65 70 75 80

Cys Tyr Val Gly Lys Asp Thr His Ala Leu Ser Glu Pro Ala Phe Ile  
85 90 95

Ser Val Leu Glu Val Leu Ala Ala Asn Gly Val Asp Val Ile Val Gln  
100 105 110

Glu Asn Asn Gly Phe Thr Pro Thr Pro Ala Val Ser Asn Ala Ile Leu  
115 120 125

Val His Asn Lys Lys Gly Gly Pro Leu Ala Asp Gly Ile Val Ile Thr  
130 135 140

Pro Ser His Asn Pro Pro Glu Asp Gly Gly Ile Lys Tyr Asn Pro Pro  
145 150 155 160

Asn Gly Gly Pro Ala Asp Thr Asn Val Thr Lys Val Val Glu Asp Arg  
165 170 175

Ala Asn Ala Leu Leu Ala Asp Gly Leu Lys Gly Val Lys Arg Ile Ser  
180 185 190

Leu Asp Glu Ala Met Ala Ser Gly His Val Lys Glu Gln Asp Leu Val  
195 200 205

Gln Pro Phe Val Glu Gly Leu Ala Asp Ile Val Asp Met Ala Ala Ile  
210 215 220

Gln Lys Ala Gly Leu Thr Leu Gly Val Asp Pro Leu Gly Gly Ser Gly  
225 230 235 240

Ile Glu Tyr Trp Lys Arg Ile Gly Glu Tyr Tyr Asn Leu Asn Leu Thr  
245 250 255

Ile Val Asn Asp Gln Val Asp Gln Thr Phe Arg Phe Met His Leu Asp  
260 265 270

Lys Asp Gly Ala Ile Arg Met Asp Cys Ser Ser Glu Cys Ala Met Ala  
275 280 285

Gly Leu Leu Ala Leu Arg Asp Lys Phe Asp Leu Ala Phe Ala Asn Asp  
290 295 300

Pro Asp Tyr Asp Arg His Gly Ile Val Thr Pro Ala Gly Leu Met Asn  
305 310 315 320

Pro Asn His Tyr Leu Ala Val Ala Ile Asn Tyr Leu Phe Gln His Arg  
325 330 335

Pro Gln Trp Gly Lys Asp Val Ala Val Gly Lys Thr Leu Val Ser Ser

340

345

350

Ala Met Ile Asp Arg Val Val Asn Asp Leu Gly Arg Lys Leu Val Glu  
355 360 365

Val Pro Val Gly Phe Lys Trp Phe Val Asp Gly Leu Phe Asp Gly Ser  
370 375 380

Phe Gly Phe Gly Gly Glu Glu Ser Ala Gly Ala Ser Phe Leu Arg Phe  
385 390 395 400

Asp Gly Thr Pro Trp Ser Thr Asp Lys Asp Gly Ile Ile Met Cys Leu  
405 410 415

Leu Ala Ala Glu Ile Thr Ala Val Thr Gly Lys Asn Pro Gln Glu His  
" 420 425 430

Tyr Asn Glu Leu Ala Lys Arg Phe Gly Ala Pro Ser Tyr Asn Arg Leu  
435 440 445

Gln Ala Ala Ala Thr Ser Ala Gln Lys Ala Ala Leu Ser Lys Leu Ser  
450 455 460

Pro Glu Met Val Ser Ala Ser Thr Leu Ala Gly Asp Pro Ile Thr Ala  
465 470 475 480

Arg Leu Thr Ala Ala Pro Gly Asn Gly Ala Ser Ile Gly Gly Leu Lys  
485 490 495

Val Met Thr Asp Asn Gly Trp Phe Ala Ala Arg Pro Ser Gly Thr Glu  
500 505 510

Asp Ala Tyr Lys Ile Tyr Cys Glu Ser Phe Leu Gly Glu Glu His Arg  
515 520 525

Lys Gln Ile Glu Lys Glu Ala Val Glu Ile Val Ser Glu Val Leu Lys  
530 535 540

Asn Ala  
545

<210> 9  
<211> 558  
<212> PRT  
<213> Escherichia coli  
<400> 9

Met Lys Leu Phe Lys Ser Ile Leu Leu Ile Ala Ala Cys His Ala Ala  
1 5 10 15

Gln Ala Ser Ala Ala Ile Asp Ile Asn Ala Asp Pro Asn Leu Thr Gly

20

25

30

Ala Ala Pro Leu Thr Gly Ile Leu Asn Gly Gln Gln Ser Asp Thr Gln  
35 40 45

Asn Met Ser Gly Phe Asp Asn Thr Pro Pro Pro Ser Pro Pro Val Val  
50 55 60

Met Ser Arg Met Phe Gly Ala Gln Leu Phe Asn Gly Thr Ser Ala Asp  
65 70 75 80

Ser Gly Ala Thr Val Gly Phe Asn Pro Asp Tyr Ile Leu Asn Pro Gly  
85 90 95

Asp Ser Ile Gln Val Arg Leu Trp Gly Ala Phe Thr Phe Asp Gly Ala  
100 105 110

Leu Gln Val Asp Pro Lys Gly Asn Ile Phe Leu Pro Asn Val Gly Pro  
115 120 125

Val Lys Val Ala Gly Val Ser Asn Ser Gln Leu Asn Ala Leu Val Thr  
130 135 140

Ser Lys Val Lys Glu Val Tyr Gln Ser Asn Val Asn Val Tyr Ala Ser  
145 150 155 160

Leu Leu Gln Ala Gln Pro Val Lys Val Tyr Val Thr Gly Phe Val Arg  
165 170 175

Asn Pro Gly Leu Tyr Gly Val Thr Ser Asp Ser Leu Leu Asn Tyr  
180 185 190

Leu Ile Lys Ala Gly Gly Val Asp Pro Glu Arg Gly Ser Tyr Val Asp  
195 200 205

Ile Val Val Lys Arg Gly Asn Arg Val Arg Ser Asn Val Asn Leu Tyr  
210 215 220

Asp Phe Leu Leu Asn Gly Lys Leu Gly Leu Ser Gln Phe Ala Asp Gly  
225 230 235 240

Asp Thr Ile Ile Val Gly Pro Arg Gln His Thr Phe Ser Val Gln Gly  
245 250 255

Asp Val Phe Asn Ser Tyr Asp Phe Glu Arg Gly Ser Ser Ile Pro  
260 265 270

Val Thr Glu Ala Leu Ser Trp Ala Arg Pro Lys Pro Gly Ala Thr His  
275 280 285

Ile Thr Ile Met Arg Lys Gln Gly Leu Gln Lys Arg Ser Glu Tyr Tyr  
290 295 300

Pro Ile Ser Ser Ala Pro Gly Arg Met Leu Gln Asn Gly Asp Thr Leu  
305 310 315 320

Ile Val Ser Thr Asp Arg Tyr Ala Gly Thr Ile Gln Val Arg Val Glu  
325 330 335

Gly Ala His Ser Gly Glu His Ala Met Val Leu Pro Tyr Gly Ser Thr  
340 345 350

Met Arg Ala Val Leu Glu Lys Val Arg Pro Asn Ser Met Ser Gln Met  
355 360 365

Asn Ala Val Gln Leu Tyr Arg Pro Ser Val Ala Gln Arg Gln Lys Glu  
370 375 380

Met Leu Asn Leu Ser Leu Gln Lys Leu Glu Glu Ala Ser Leu Ser Ala  
385 390 395 400

Gln Ser Ser Thr Lys Glu Glu Ala Ser Leu Arg Met Gln Glu Ala Gln  
405 410 415

Leu Ile Ser Arg Phe Val Ala Lys Ala Arg Thr Val Val Pro Lys Gly  
420 425 430

Glu Val Ile Leu Asn Glu Ser Asn Ile Asp Ser Val Leu Leu Glu Asp  
435 440 445

Gly Asp Val Ile Asn Ile Pro Glu Lys Thr Ser Leu Val Met Val His  
450 455 460

Gly Glu Val Leu Phe Pro Asn Ala Val Ser Trp Gln Lys Gly Met Thr  
465 470 475 480

Thr Glu Asp Tyr Ile Glu Lys Cys Gly Gly Leu Thr Gln Lys Ser Gly  
485 490 495

Asn Ala Arg Ile Ile Val Ile Arg Gln Asn Gly Ala Ala Val Asn Ala  
500 505 510

Glu Asp Val Asp Ser Leu Lys Pro Gly Asp Glu Ile Met Val Leu Pro  
515 520 525

Lys Tyr Glu Ser Lys Asn Ile Glu Val Thr Arg Gly Ile Ser Thr Ile  
530 535 540

Leu Tyr Gln Leu Ala Val Gly Ala Lys Val Ile Leu Ser Leu

545

550

555

<210> 10  
<211> 207  
<212> PRT  
<213> Escherichia coli  
<400> 10

Met Ser Lys Lys Leu Ile Ile Phe Gly Ala Gly Gly Phe Ser Lys Ser  
5 10 15  
1

Ile Ile Asp Ser Leu Asn His Lys His Tyr Glu Leu Ile Gly Phe Ile  
20 25 30

Asp Lys Tyr Lys Ser Gly Tyr His Gln Ser Tyr Pro Ile Leu Gly Asn  
35 40 45

Asp Ile Ala Asp Ile Glu Asn Lys Asp Asn Tyr Tyr Phe Ile Gly  
50 55 60

Ile Gly Lys Pro Ser Thr Arg Lys His Tyr Leu Asn Ile Ile Arg Lys  
65 70 75 80

His Asn Leu Arg Leu Ile Asn Ile Ile Asp Lys Thr Ala Ile Leu Ser  
85 90 95

Pro Asn Ile Ile Leu Gly Asp Gly Ile Phe Ile Gly Lys Met Cys Ile  
100 105 110

Leu Asn Arg Asp Thr Arg Ile His Asp Ala Val Val Ile Asn Thr Arg  
115 120 125

Ser Leu Ile Glu His Gly Asn Glu Ile Gly Cys Cys Ser Asn Ile Ser  
130 135 140

Thr Asn Val Val Leu Asn Gly Asp Val Ser Val Gly Glu Glu Thr Phe  
145 150 155 160

Val Gly Ser Val Thr Val Val Asn Gly Gln Leu Lys Leu Gly Ser Lys  
165 170 175

Ser Ile Ile Gly Ser Gly Ser Val Val Ile Arg Asn Ile Pro Ser Asn  
180 185 190

Val Val Val Ala Gly Thr Pro Thr Arg Leu Ile Arg Gly Asn Glu  
195 200 205

<210> 11  
<211> 191  
<212> PRT  
<213> Escherichia coli  
<400> 11

Met Ala Lys Ser Val Pro Ala Ile Phe Leu Asp Arg Asp Gly Thr Ile  
1 5 10 15

Asn Val Asp His Gly Tyr Val His Glu Ile Asp Asn Phe Glu Phe Ile  
20 25 30

Asp Gly Val Ile Asp Ala Met Arg Glu Leu Lys Lys Met Gly Phe Ala  
35 40 45

Leu Val Val Val Thr Asn Gln Ser Gly Ile Ala Arg Gly Lys Phe Thr  
50 55 60

Glu Ala Gln Phe Glu Thr Leu Thr Glu Trp Met Asp Trp Ser Leu Ala  
65 70 75 80

Asp Arg Asp Val Asp Leu Asp Gly Ile Tyr Tyr Cys Pro His His Pro  
85 90 95

Gln Gly Ser Val Glu Glu Phe Arg Gln Val Cys Asp Cys Arg Lys Pro  
100 105 110

His Pro Gly Met Leu Leu Ser Ala Arg Asp Tyr Leu His Ile Asp Met  
115 120 125

Ala Ala Ser Tyr Met Val Gly Asp Lys Leu Glu Asp Met Gln Ala Ala  
130 135 140

Val Ala Ala Asn Val Gly Thr Lys Val Leu Val Arg Thr Gly Lys Pro  
145 150 155 160

Ile Thr Pro Glu Ala Glu Asn Ala Ala Asp Trp Val Leu Asn Ser Leu  
165 170 175

Ala Asp Leu Pro Gln Ala Ile Lys Lys Gln Gln Lys Pro Ala Gln  
180 185 190

<210> 12  
<211> 310  
<212> PRT  
<213> Escherichia coli  
<400> 12

Met Ile Ile Val Thr Gly Gly Ala Gly Phe Ile Gly Ser Asn Ile Val  
1 5 10 15

Lys Ala Leu Asn Asp Lys Gly Ile Thr Asp Ile Leu Val Val Asp Asn  
20 25 30

Leu Lys Asp Gly Thr Lys Phe Val Asn Leu Val Asp Leu Asn Ile Ala  
35 40 45

Asp Tyr Met Asp Lys Glu Asp Phe Leu Ile Gln Ile Met Ala Gly Glu  
50 55 60

Glu Phe Gly Asp Val Glu Ala Ile Phe His Glu Gly Ala Cys Ser Ser  
65 70 75 80

Thr Thr Glu Trp Asp Gly Lys Tyr Met Met Asp Asn Asn Tyr Gln Tyr  
85 90 95

Ser Lys Glu Leu Leu His Tyr Cys Leu Glu Arg Glu Ile Pro Phe Leu  
100 105 110

Tyr Ala Ser Ser Ala Ala Thr Tyr Gly Gly Arg Thr Ser Asp Phe Ile  
115 120 125

Glu Ser Arg Glu Tyr Glu Lys Pro Leu Asn Val Tyr Gly Tyr Ser Lys  
130 135 140

Phe Leu Phe Asp Glu Tyr Val Arg Gln Ile Leu Pro Glu Ala Asn Ser  
145 150 155 160

Gln Ile Val Gly Phe Arg Tyr Phe Asn Val Tyr Gly Pro Arg Glu Gly  
165 170 175

His Lys Gly Ser Met Ala Ser Val Ala Phe His Leu Asn Thr Gln Leu  
180 185 190

Asn Asn Gly Glu Ser Pro Lys Leu Phe Glu Gly Ser Glu Asn Phe Lys  
195 200 205

Arg Asp Phe Val Tyr Val Gly Asp Val Ala Asp Val Asn Leu Trp Phe  
210 215 220

Leu Glu Asn Gly Val Ser Gly Ile Phe Asn Leu Gly Thr Gly Arg Ala  
225 230 235 240

Glu Ser Phe Gln Ala Val Ala Asp Ala Thr Leu Ala Tyr His Lys Lys  
245 250 255

Gly Gln Ile Glu Tyr Ile Pro Phe Pro Asp Lys Leu Lys Gly Arg Tyr  
260 265 270

Gln Ala Phe Thr Gln Ala Asp Leu Thr Asn Leu Arg Ala Ala Gly Tyr  
275 280 285

Asp Lys Pro Phe Lys Thr Val Ala Glu Gly Val Thr Glu Tyr Met Ala  
290 295 300

Trp Leu Asn Arg Asp Ala

305

310

<210> 13  
<211> 477  
<212> PRT  
<213> Escherichia coli  
<400> 13

Met Lys Val Thr Leu Pro Glu Phe Glu Arg Ala Gly Val Met Val Val  
1 5 10 15

Gly Asp Val Met Leu Asp Arg Tyr Trp Tyr Gly Pro Thr Ser Arg Ile  
20 25 30

Ser Pro Glu Ala Pro Val Pro Val Val Lys Val Asn Thr Ile Glu Glu  
35 40 45

Arg Pro Gly Gly Ala Ala Asn Val Ala Met Asn Ile Ala Ser Leu Gly  
50 55 60

Ala Asn Ala Arg Leu Val Gly Leu Thr Gly Ile Asp Asp Ala Ala Arg  
65 70 75 80

Ala Leu Ser Lys Ser Leu Ala Asp Val Asn Val Lys Cys Asp Phe Val  
85 90 95

Ser Val Pro Thr His Pro Thr Ile Thr Lys Leu Arg Val Leu Ser Arg  
100 105 110

Asn Gln Gln Leu Ile Arg Leu Asp Phe Glu Glu Gly Phe Glu Gly Val  
115 120 125

Asp Pro Gln Pro Leu His Glu Arg Ile Asn Gln Ala Leu Ser Ser Ile  
130 135 140

Gly Ala Leu Val Leu Ser Asp Tyr Ala Lys Gly Ala Leu Ala Ser Val  
145 150 155 160

Gln Gln Met Ile Gln Leu Ala Arg Lys Ala Gly Val Pro Val Leu Ile  
165 170 175

Asp Pro Lys Gly Thr Asp Phe Glu Arg Tyr Arg Gly Ala Thr Leu Leu  
180 185 190

Thr Pro Asn Leu Ser Glu Phe Glu Ala Val Val Gly Lys Cys Lys Thr  
195 200 205

Glu Glu Glu Ile Val Glu Arg Gly Met Lys Leu Ile Ala Asp Tyr Glu  
210 215 220

Leu Ser Ala Leu Leu Val Thr Arg Ser Glu Gln Gly Met Ser Leu Leu

225

230

235

240

Gln Pro Gly Lys Ala Pro Leu His Met Pro Thr Gln Ala Gln Glu Val  
245 250 255

Tyr Asp Val Thr Gly Ala Gly Asp Thr Val Ile Gly Val Leu Ala Ala  
260 265 270

Thr Leu Ala Ala Gly Asn Ser Leu Glu Glu Ala Cys Phe Phe Ala Asn  
275 280 285

Ala Ala Ala Gly Val Val Val Gly Lys Leu Gly Thr Ser Thr Val Ser  
290 295 300

Pro Ile Glu Leu Glu Asn Ala Val Arg Gly Arg Ala Asp Thr Gly Phe  
305 310 315 320

Gly Val Met Thr Glu Glu Leu Lys Leu Ala Val Ala Ala Ala Arg  
325 330 335

Lys Arg Gly Glu Lys Val Val Met Thr Asn Gly Val Phe Asp Ile Leu  
340 345 350

His Ala Gly His Val Ser Tyr Leu Ala Asn Ala Arg Lys Leu Gly Asp  
355 360 365

Arg Leu Ile Val Ala Val Asn Ser Asp Ala Ser Thr Lys Arg Leu Lys  
370 375 380

Gly Asp Ser Arg Pro Val Asn Pro Leu Glu Gln Arg Met Ile Val Leu  
385 390 395 400

Gly Ala Leu Glu Ala Val Asp Trp Val Val Ser Phe Glu Glu Asp Thr  
405 410 415

Pro Gln Arg Leu Ile Ala Gly Ile Leu Pro Asp Leu Leu Val Lys Gly  
420 425 430

Gly Asp Tyr Lys Pro Glu Glu Ile Ala Gly Ser Lys Glu Val Trp Ala  
435 440 445

Asn Gly Gly Glu Val Leu Val Leu Asn Phe Glu Asp Gly Cys Ser Thr  
450 455 460

Thr Asn Ile Ile Lys Lys Ile Gln Gln Asp Lys Lys Gly  
465 470 475

<210> 14  
<211> 420  
<212> PRT

<213> Escherichia coli

<400> 14

Met Leu Lys Arg Leu Gly Lys Val Phe Gly Pro Leu Val Cys Ala Leu  
1 5 10 15

Leu Leu Leu Val Gly Leu Tyr Leu Val Phe Pro Val Ser Gln Pro His  
20 25 30

His Leu Gly Lys Glu Lys Asn Ser Ala Val Ala Leu Thr Lys Ala Gly  
35 40 45

Phe Lys Ser Arg Val Gln Lys Val Arg Ala Phe Ser Asp Pro Lys Ala  
50 55 60

Asn Phe Val Pro Phe Phe Gly Ser Ser Glu Trp Leu Arg Phe Asp Ala  
65 70 75 80

Met His Pro Ser Val Leu Ala Glu Ala Tyr Lys Arg Pro Tyr Ile Pro  
85 90 95

Tyr Leu Leu Gly Gln Lys Gly Ala Ala Ser Leu Thr Gln Tyr Tyr Gly  
100 105 110

Ile Gln Gln Ile Lys Gly Gln Ile Lys Asn Lys Lys Ala Ile Tyr Val  
115 120 125

Ile Ser Pro Gln Trp Phe Val Arg Lys Gly Ala Asn Lys Gly Ala Phe  
130 135 140

Gln Asn Tyr Phe Ser Asn Asp Gln Thr Ile Arg Phe Leu Gln Asn Gln  
145 150 155 160

Thr Gly Thr Tyr Asp Arg Tyr Ala Ala Arg Arg Leu Leu Lys Leu  
165 170 175

Tyr Pro Glu Ala Ser Met Ser Asp Leu Ile Glu Lys Val Ala Asp Gly  
180 185 190

Gln Lys Leu Ser Asn Lys Asp Lys Gln Arg Leu Lys Phe Asn Asp Trp  
195 200 205

Val Phe Glu Lys Thr Asp Ala Ile Phe Ser Tyr Leu Pro Leu Gly Lys  
210 215 220

Thr Tyr Asn Gln Val Ile Met Pro His Val Gly Lys Leu Pro Lys Ala  
225 230 235 240

Phe Ser Tyr Asn His Leu Ser Arg Ile Ala Ser Gln Asp Ala Lys Val  
245 250 255

Ala Thr Arg Ser Asn Gln Phe Gly Ile Asp Asp Arg Phe Tyr Gln Thr  
260 265 270

Arg Ile Lys Lys His Leu Lys Leu Lys Gly Ser Gln Arg His Phe  
275 280 285

Asn Tyr Thr Lys Ser Pro Glu Phe Asn Asp Leu Gln Leu Val Leu Asn  
290 295 300

Glu Phe Ser Lys Gln Asn Thr Asp Val Leu Phe Val Ile Pro Pro Val  
305 310 315 320

Asn Lys Lys Trp Thr Asp Tyr Thr Gly Leu Asp Gln Lys Met Tyr Gln  
325 330 335

Lys Ser Val Glu Lys Ile Lys His Gln Leu Gln Ser Gln Gly Phe Asn  
340 345 350

His Ile Ser Asp Leu Ser Arg Asp Gly Gly Lys Pro Tyr Phe Met Gln  
355 360 365

Asp Thr Ile His Leu Gly Trp Asn Gly Trp Leu Glu Leu Asp Lys His  
370 375 380

Ile Asn Pro Phe Leu Thr Glu Glu Asn Ser Lys Pro Asn Tyr His Ile  
385 390 395 400

Asn Asn Lys Phe Leu Lys Arg Ser Trp Ala Lys Tyr Thr Gly Arg Pro  
405 410 415

Ser Asp Tyr Lys  
420

<210> 15  
<211> 511  
<212> PRT  
<213> Escherichia coli  
<400> 15

Met Ile His Asp Met Ile Lys Thr Ile Glu His Phe Ala Glu Thr Gln  
1 5 10 15

Ala Asp Phe Pro Val Tyr Asp Ile Leu Gly Glu Val His Thr Tyr Gly  
20 25 30

Gln Leu Lys Val Asp Ser Asp Ser Leu Ala Ala His Ile Asp Ser Leu  
35 40 45

Gly Leu Val Glu Lys Ser Pro Val Leu Val Phe Gly Gly Gln Glu Tyr  
50 55 60

Glu Met Leu Ala Thr Phe Val Ala Leu Thr Lys Ser Gly His Ala Tyr  
65 70 75 80

Ile Pro Val Asp Gln His Ser Ala Leu Asp Arg Ile Gln Ala Ile Met  
85 90 95

Thr Val Ala Gln Pro Ser Leu Ile Ile Ser Ile Gly Glu Phe Pro Leu  
100 105 110

Glu Val Asp Asn Val Pro Ile Leu Asp Val Ser Gln Val Ser Ala Ile  
115 120 125

Phe Glu Glu Lys Thr Pro Tyr Glu Val Thr His Ser Val Lys Gly Asp  
130 135 140

Asp Asn Tyr Tyr Ile Ile Phe Thr Ser Gly Thr Thr Gly Leu Pro Lys  
145 150 155 160

Gly Val Gln Ile Ser His Asp Asn Leu Leu Ser Phe Thr Asn Trp Met  
165 170 175

Ile Ser Asp Asp Glu Phe Ser Val Pro Glu Arg Pro Gln Met Leu Ala  
180 185 190

Gln Pro Pro Tyr Ser Phe Asp Leu Ser Val Met Tyr Trp Ala Pro Thr  
195 200 205

Leu Ala Met Gly Gly Thr Leu Phe Ala Leu Pro Lys Thr Val Val Asn  
210 215 220

Asp Phe Lys Lys Leu Phe Ala Thr Ile Asn Glu Leu Pro Ile Gln Val  
225 230 235 240

Trp Thr Ser Thr Pro Ser Phe Ala Asp Met Ala Leu Leu Ser Asn Asp  
245 250 255

Phe Asn Ser Glu Thr Leu Pro Gln Leu Thr His Phe Tyr Phe Asp Gly  
260 265 270

Glu Glu Leu Thr Val Lys Thr Ala Gln Lys Leu Arg Gln Arg Phe Pro  
275 280 285

Lys Ala Arg Ile Val Asn Ala Tyr Gly Pro Thr Glu Ala Thr Val Ala  
290 295 300

Leu Ser Ala Val Ala Ile Thr Asp Glu Met Leu Glu Thr Cys Lys Arg  
305 310 315 320

Leu Pro Ile Gly Tyr Thr Lys Asp Asp Ser Pro Thr Tyr Val Ile Asp

325

330

335

Glu Glu Gly His Lys Leu Pro Asn Gly Glu Gln Gly Glu Ile Ile Ile  
 340 345 350

Ala Gly Pro Ala Val Ser Lys Gly Tyr Leu Asn Asn Pro Glu Lys Thr  
 355 360 365

Ala Glu Ala Phe Phe Gln Phe Glu Gly Leu Pro Ala Tyr His Thr Gly  
 370 375 380

Asp Leu Gly Ser Met Thr Asp Glu Gly Leu Leu Tyr Gly Gly Arg  
 385 390 395 400

Met Asp Phe Gln Ile Lys Phe Asn Gly Tyr Arg Ile Glu Leu Glu Asp  
 405 410 415

Val Ser Gln Asn Leu Asn Lys Ser Gln Tyr Val Lys Ser Ala Val Ala  
 420 425 430

Val Pro Arg Tyr Asn Lys Asp His Lys Val Gln Asn Leu Leu Ala Tyr  
 435 440 445

Ile Val Leu Lys Glu Gly Val Arg Asp Asp Phe Glu Arg Asp Leu Asp  
 450 455 460

Leu Thr Lys Ala Ile Lys Glu Asp Leu Lys Asp Ile Met Met Asp Tyr  
 465 470 475 480

Met Met Pro Ser Lys Phe Ile Tyr Arg Glu Asp Leu Pro Leu Thr Pro  
 485 490 495

Asn Gly Lys Ile Asp Ile Lys Gly Leu Met Ser Glu Val Asn Lys  
 500 505 510

<210> 16

<211> 919

<212> DNA

<213> Escherichia coli

<400> 16

ggccgcactc actgatgccc agcaggcaat cccaggatt aagtttact ggggggttga 60  
 agaagggttc gcacagattc cttctggca cgctgcgtt gagcgagttt ttcctgtggc 120  
 aatacgtcgc tggcgtaaag cctggttctc ggccccata aaagctgaac gcaaagcgtt 180  
 tcgtgaagcg ctacaaggcag agaactatga cgcagttatc gacgctcagg ggctggtaaa 240  
 aagcgccgca ctggtgacac gtctggcgca tggcgtaaag catggattgg actggcaaac 300  
 cgctcgcgaa ccttagcca gcctgttttta caattgttaag catcatattg caaaacagca 360  
 gcacgcccgtt gaacgcaccc gcgaactgtt tgccaaaagt ttgggctata gcaaaccgca 420

aacccagggc	gattatgcta	tcgcacagca	ttttctgacg	aacctgccta	cagatgctgg	480
cgaatatgcc	gtatttcttc	atgcgacgac	ccgtgatgat	aaacactggc	cggaagaaca	540
ctggcgagaa	ttgattggtt	tactggctga	ttcaggaata	cggattaaac	ttccgtgggg	600
cgccgcgcac	gaggaagaac	ggcgaaacg	actggcggaa	ggatttgctt	atgttgaagt	660
attgccgaag	atgagtcgtgg	aaggcggtgc	ccgcgtgctg	gccggggcta	aattttagt	720
gtcggtggat	acgggggttaa	gccatthaac	ggcggcactg	gatagaccca	atatcacggt	780
ttatggacca	accgatccgg	gattaattgg	tgggtatggg	aagaatcaga	tggttttag	840
ggctccgggg	aatgagttgt	ctcaattgac	agcaaatgct	gttaagcggt	tcattgaaga	900
aaacgctgcc	atgatttaa					919

<210>	17					
<211>	1023					
<212>	DNA					
<213>	Escherichia coli					
<400>	17					
atgcgttttc	atggggatat	gttattaact	actcccgta	ttagttcgct	aaaaaaaaat	60
taccctgacg	caaaaatcga	tgtgctgctt	tatcaggaca	ccatcccgat	cctgtctgaa	120
aatccagaga	ttaacgcgt	ctacggcata	aaaaataaaa	aagcaaaagc	ctcagaaaaa	180
attgccaact	tttttcatct	catcaaggta	ttacgtgcca	ataagtatga	ccttatacg	240
aatctcaccg	atcaatggat	ggttgctata	ctggttcgct	tattaaatgc	ccgtgtgaaa	300
atttcccagg	attatcatca	tcggcagtct	gcttttggc	gtaaaagttt	caccatttg	360
gtgccgttgc	agggtggaaa	tgtggtgaa	agtaacttat	ccgtgctgac	cccatggga	420
gttgattcgt	tggtaagca	gacaaccatg	agttacccgc	ctgcaagctg	gaaacgtatg	480
cgtcgcaac	ttgatcacgc	tggtgttgg	caaattatg	tggttatcca	acctacggcg	540
cggcaaatct	tcaaattgctg	ggacaacgccc	aagtttccg	ctgtgattga	tgccttacat	600
gctcgtggtt	atgaagttgt	tctgacgtcc	ggcccagata	aagacgatct	ggcctgcgtc	660
aatgaaattg	cgcagggatg	ccagacgcca	ccagtaacgg	cgctggctgg	aaaggtgacc	720
ttcccggaac	ttgggtgcgtt	aatcgatcat	gcccagctgt	ttattggcgt	tgattccgca	780
ccggcgcata	ttgccgcgtc	agttaatacg	ccgctgatata	cgctgtttgg	tgcgacagac	840
catatttct	ggcgccccgt	gtcaaataac	atgattcaat	tctggggcggg	agattaccgg	900
gaaatgccaa	cgcgcgatca	gcgtgaccga	aatgagatgt	atcttcgggt	tattccggcg	960
gcagatgtca	ttgctgctgt	cgataaatta	ctgccctcct	ccacgacagg	tacgtcgta	1020
tga						1023

<210>	18					
<211>	798					
<212>	DNA					

<213> Escherichia coli  
<400> 18

atggttgaac ttAAAGAGCC	60
gttAAACCT TGCAGGGTGA	120
gaaATGGCGG GCAAAAGCTA	180
atcaAAAATT TACTCTCATT	240
attCATCGAC TGCAGGGATGT	300
ggcatGAATC CGCTGACCAAG	360
agtCTGGAAG ATTACTGTGC	420
atGCTTATTa AGCGTGTcGC	480
cgtGACTGTT ATATCTGTCA	540
ttaAAAATTt CGGTAATTGA	600
tggCGGGATA AAGATCTTAT	660
cggGATATCT GGCGGTTAT	720
cagGAACAAG GACTGCTGTC	780
attCGAAAAT CGTTGAA	798

<210> 19  
<211> 1125  
<212> DNA  
<213> Escherichia coli  
<400> 19

atGATCGTTG CTTTTGTTT	60
atGCGTATTG CTCAGACAGT	120
tggGAAGGCG AATGCCCTGA	180
aATCACGGGC GCAATGCGGA	240
gtcGATAAAG TCGTTGGATT	300
gtttGTTATG CCGAGAAAAGT	360
tATGCCATT ATGCCCTT	420
ctGATGCTGA CAGATAAGCA	480
cgTTTCTATA TTCTGCCACC	540
aatAGCCGTG AAATCTCCG	600
caggTCGGTT CAGACTTCAC	660
ttACCGGATT CGCTGCGCCA	720
aaATTTGAGG CACTGGCAGA	780
cgcaACGATG TCTCGGAATT	840

gaagcggcgg gaatttgtct gctggaaagcg attactgcag gattaccggc actaacaact 900  
 gccgtttgtg gctatgcgca ttatattgtc gacgctaatt gcggcgaggc tattgctgag 960  
 ccattccgccc aggaaacatt gaatgagatt ttacgcaaag cgttaacgca atcttcattg 1020  
 cggcaggcgtt gggcgaaaaa tgcgcgacat tatgctgata cacaagattt atacagtctg 1080  
 ccagagaaag cggcggatata cataacgggt ggtctggatg gttga 1125

<210> 20  
 <211> 1047  
 <212> DNA  
 <213> Escherichia coli  
 <400> 20

atgaaaatac tggtgatcgg cccgtcttgg gttggcgaca tgatgatgtc gcaaagtctc 60  
 tatcgacacgc tccaggcgcg ctatccccag gcgataatcg atgtgatggc accggcatgg 120  
 tgccgtccat tattatcgcg gatgccggaa gttaacgaag ctattcctat gcctctcggt 180  
 cacggagcgc tggaaatcgg cgaacgcccgc aaactgggtc atagcctgcg tgaaaagcgc 240  
 tacgaccgcg cctacgtctt acccaactcc ttcaaattctg cattagtgcc tttcttcgcg 300  
 ggtattcctc atcgacccgg ctggcgccggc gagatgcgct acggtttact caacgatgta 360  
 cgcgtgcgcg ataaaagaagc ctggccgcta atgggtggaaac gctatatagc gctggcctat 420  
 gacaaaggca ttatgcgcac agcacaagat ctgcccgcagc cattgtttag gccgcagttg 480  
 caggtgagcg aaggtaaaaa atcatataacc tgtaatcaat tttcgcttgc atcagaacgt 540  
 ccgatgattt gtttttgcggg ggggtgcggag tttggtccgg caaaacgctg gccacactac 600  
 cactatgcgg agctggcaaa gcagctgatt gatgaagggtt atcaggtggc tctgtttggc 660  
 tcggcgaaag atcatgaagc gggcaatgag attcttgcgg ctttgaatac cgagcagcag 720  
 gcatggtgac ggaacctggc gggggaaaca cagcttgcgc aagcggttat cctgattgca 780  
 gcctgtaaag ccattgtcac taacgattct ggccgtatgc atgttgcggc ggcgcctcaat 840  
 cgtccgctgg ttgcctgtt tggtccgagt agcccgact tcacaccgccc gctatcccat 900  
 aaagcgcgcg tgatccgttt gattaccggc tatcacaagg tgcgtaaagg tgacgctgcg 960  
 gaggggttatac accagagctt aatcgacatt actccccagc gcgtactgga agaactcaac 1020  
 gcgcattgt tacaagagga agcctga 1047

<210> 21  
 <211> 1017  
 <212> DNA  
 <213> Escherichia coli  
 <400> 21

atgagtgccc actattttaa tccacaagag atgatcaata agacaatcat cttcgatgaa 60  
 aggcgcggcgg cgtcagtggc atcatcatcc catgttgctt atggcattga taaaaacttt 120  
 ctttttgggtt gtgggttttc aatcacgtca gttttgttac ataacaacgaa cgtgagttt 180

gttttccacg ttttattga tgatatccct gaagccgata tccagcgaaaattg	240
gcgaaaagct atcgtacctg tatccagatc catctagtaa attgtgaacg gcttaaggca	300
ttaccgacga ccaaaaattg gtctattgcc atgtattcc gttttgtaat tgcagattac	360
tttattgatc aacaagataa gatcctttac ctggatgctg atatgcctg tcaggaaac	420
ttaaagccgc tgataacaat ggatcttgcc aataacgttg ctgctgttgt tactgaacgc	480
gatgctaact ggtggtcgtt acggggtcaa agtctgcagt gtaatgaact taaaaagggt	540
tactttaatt caggtgtcct gttaattaat acactagcgt gggcgcagga gtccgtttct	600
gctaaagcga tgcgtatgct tgctgataaa gccatcgaaa cccgtttaac ctatatggat	660
caagatatcc ttaatcttat cctgttaggg aaagtttaat tcattgatgc taaataacaat	720
acgcaatttta gtttaaatta tgaattaaaa aaatcatttg tttgtccaaat taatgatgaa	780
accgtattaa ttcattatgt cggcccgaca aaaccctggc attactggc cggttatcca	840
agtgcgcaac ctttatcaa agccaaagaa gcatcgccct ggaaaaatga accgttaatg	900
cggccagtttta actcaaacta tgctcgatgct tgcgccaagc ataattttaa acaaaaacaaa	960
ccaaattaaacg ggataatgaa ttatattttaattttaat taaagataat aaaatga	1017

<210> 22  
 <211> 909  
 <212> DNA  
 <213> Escherichia coli  
 <400> 22

atggctgcca ttaatacgaa agtcaaaaaa gccgttatcc ccgttgcggg attaggaacc	60
aggatgttgc cggcgacgaa agccatcccg aaagagatgc tgccacttgt cgataagcca	120
ttaattcaat acgtcgtgaa tgaatgtatt gcggctggca ttactgaaat tgcgtcggtt	180
acacactcat ctaaaaaactc tattgaaaaac cactttgata ccagtttga actggaagca	240
atgctggaaa aacgtgtaaa acgtcaactg cttgtatgaag tgcagtcata ttgtccaccg	300
cacgtgacta ttatgcaagt tcgtcagggt ctggcgaaag gcctgggaca cgcggatttg	360
tgcgtcacc cggtagtggg tcatgtaccg ttagctgtta ttttgcctga tgcgttctg	420
gatgaatatg aatccgattt gtcacaggat aacctggcag agatgatccg ccgtttgtat	480
gaaacgggtc atagccagat catggttgaa ccgggttgcgt atgtgaccgc atatggcggt	540
gtggattgca aaggcggttga attagcgccg ggtgaaagcg taccgatggc tgggtgtggta	600
gaaaaaccga aagcggatgt tgcgtccgtct aatctcgcta ttgtgggtcg ttacgtactt	660
agcgcggata tttggccgtt gctggcaaaa acccctccgg gagctggtga tggaaattcag	720
ctcaccgacg caattgatat gctgatcgaa aaagaaaacgg tggaaagccta tcataatgaaa	780
ggaaagagcc atgactgcgg taataaattt ggttacatgc aggccttcgt tgaataacgg	840
attcgtcata acacccttgg cacggattt aaagcctggc ttgaagaaga gatgggcatt	900
aagaagttaa	909

<210> 23  
<211> 1641  
<212> DNA  
<213> Escherichia coli  
<400> 23

atggcaatcc acaatcggtgc aggccaaacct gcacaacaga gtgatttgat taacgtcgcc 60  
caactgacgg cgcaatatta tgtactgaaa ccagaagcag ggaatgcgga gcacgcggtg 120  
aaattcggta cttccggta cctgtggcagt gcagcgcgccc acagctttaa cgagccgcac 180  
attctggcga tcgctcaggc aattgctgaa gaacgtgcga aaaacggcat cactggccct 240  
tgctatgtgg gtaaaagatac tcacgcctg tccgaacctg cattcatttc cgttctggaa 300  
gtgctggcag cgaacggcgt tgatgtcatt gtgcaggaaa acaatggctt caccggacg 360  
cctggcgttt ccaatgccat cctggttcac aataaaaaaag gtggcccgct ggcagacgg 420  
atcgtgattt caccgtccca taacccgccc gaagatggtg gaatcaaata caatccgcca 480  
aatggtggcc cggctgatac caacgtcact aaagtggtg aagacaggc caacgcactg 540  
ctggccgatg gcctgaaagg cgtgaagcgt atctccctcg acgaagcgtt ggcattccgg 600  
catgtgaaag agcaggatct ggtcagccg ttcgtgaaag gtctggccga tatcgttgc 660  
atggccgca ttcagaaagc gggcctgacg ctggcggtt atccgctggg cggttccgg 720  
atcgaataact ggaagcgtat tggcgagttt tacaacctca acctgactat cgttaacgt 780  
caggtcgatc aaaccttccg ctttatgcac ctgtataaag acggcgcat ccgtatggac 840  
tgctcctccg agtgtgcgtt ggcggccctg ctggcactgc gtgataagtt cgatctggcg 900  
tttgctaaacg acccggatta tgaccgtcac ggtatcgta ctccggcagg tttgatgaat 960  
ccgaaccact acctggcggt ggcaatcaat tacctgttcc agcatcgcc gcagtggggc 1020  
aaagatgttg ccgtcggtaa aacgctggtt tcatctgcga tgatcgaccg tgggtcaac 1080  
gacttggcc gtaaactggt agaagtcggc gttaggtttca aatggttgt cgatggctg 1140  
ttcgacggca gcttcggctt tggcgccgaa gagagtgcag gggcttcctt cctgcgttcc 1200  
gacggcacgc cgtggtccac cgacaaagac ggcattcatca tgggtctgct ggcggcgaa 1260  
atcaccgctg tcaccggtaa gaacccgcag gaacactaca acgaactggc aaaacgcctt 1320  
ggtgcgcgca gctacaaccg tttgcaggca gctgcgactt ccgcacaaaa agcggcgctg 1380  
tctaagctgt ctccggaaat ggtgagcgcc agcaccctgg caggtgaccc gatcaccgac 1440  
cgccctgactg ctgctccggg caacggtgct tctattggcg gtctgaaagt gatgactgac 1500  
aacggctggc tccgtcgcc tccgtcaggc acggaagacg catataagat ctactgcgaa 1560  
agcttcctcg gtgaagaaca tcgcaagcag attgagaaag aagcggttga gattgttagc 1620  
gaagttctga aaaacgcgtaa a 1641

<211> 1677  
<212> DNA  
<213> Escherichia coli  
<400> 24

atgaaaattat ttaaatcaat tttactgatt gccgcctgtc acgcggcgca ggccagcg 60  
gccattgata ttaacgctga cccaaacctt acaggagccg cgccgcttac cggtattctg 120  
aacgggcaac agtcggatac gcaaaacatg agcggctcg acaatacccc gccgcctca 180  
ccgcccgtgg taatgagccg tatgttttgt gctcaacttt tcaacggcac cagcgcggat 240  
agcgggtgcga cggttaggatt caaccctgac tatattctga atccgggtga tagcattcag 300  
gttcgcttgcgtt ggggtgcgtt caccttgat ggtgcgttac aggttgcgttcc caaaggtaat 360  
attttcctgc cgaacgttgg tccgggtggaa gttgctggcg tcagtaatacg tcagctaaat 420  
gccctggtca catccaaagt gaaggaagta taccagtcca acgtcaacgt ctacgcctcc 480  
ttattacagg cgcagccagt aaaagtgtac gtgaccggat ttgtgcgttac tcctggtctg 540  
tatggcggtg tgacgtctga ttcgttactc aattatctga tcaaggctgg cggcggttgcgtt 600  
ccagagcgcg gaagttacgt tgatattgtg gtcaagcgcg gtaaccgcgt ggcgttccaaac 660  
gtcaacctgt acgacttcct gctgaacggc aaactggggc tttcgcagtt cgccgatgg 720  
gacaccatca tcgtcgggccc gcgtcagcat actttcagcg ttcagggcga tgcgttttac 780  
agctacgact ttgagttccg cgaaagcagc attcccgtaa cggaagcggtt gagctggcg 840  
cgccctaagc ctggcgac tcacattacg attatgcgtt aacaggggtt gcaaaaacgc 900  
agcgaataact atccgatcag ttctgcgcca ggcgttatgt tgcaaaatgg cgataccctt 960  
atcgtgagca ctgaccgcta tgccggcacc attcaggtgc gggttgaagg cgcacactcc 1020  
ggtaacatg ccatggtaact gccttatgtt tccactatgc gtgcggttct ggaaaaagtc 1080  
cgccccgaaca gcatgtcgca gatgaacgcg gttcagcttt atcgcccatc agtagctcag 1140  
cgtcagaaag agatgctgaa tctctcgctg caaaaactgg aggaagcatc actttctgcc 1200  
cagtcctcca ccaaagaaga agccagcctg cgaatgcagg aagcgcaact gatcagccgc 1260  
tttgcgttgcga aagcacgcac cgtagttccg aaaggtgaag tgatcctcaa cgaatccaaat 1320  
attgattctg ttctgcttgcgtt agatggcgac gtcataata ttccggagaa aacatcgctg 1380  
gttatggttc atggcgaagt gctgttcccg aacgcgggtga gctggcagaa gggtatgacc 1440  
accgaggatt acatcgagaa atgtgggtggc ctgacgcaga aatcggttac cgccagaatt 1500  
atcgtcattc gtcagaacgg tgctgcgtc aacgcagaag atgtggattc actcaaaccg 1560  
ggcgatgaga ttatggttct gccgaaatat gaatcgaaaa acattgaagt taccctgtgtt 1620  
atttccacca tcctctatca gctggcggtg ggtgcggaaatgg tgattctgtc ttgttac 1677

<210> 25  
<211> 624  
<212> DNA  
<213> Escherichia coli

&lt;400&gt; 25

atgagtaaaa agttaataat atttggtgcg ggtgggtttt caaaatctat aattgacagc	60
ttaaatcata aacattacga gttaatagga tttatcgata aatataaaag tggttatcat	120
caatcatatc caatattagg taatgatatt gcagacatcg agaataagga taattattat	180
tattttatttggataggcaa accatcaact aggaagcact atttaaacat cataagaaaa	240
cataatctac gcttaattaa cattatagat aaaactgcta ttctatcacc aaatattata	300
ctgggtgatg gaatttttat tggtaaaatg tgtatactta accgtgatac tagaatacat	360
gatgccgttg taataaatac taggagtttta attgaacatg gtaatgaaat aggctgctgt	420
agcaatatct ctactaatgt tgtacttaat ggtgatgtt ctgttggaga agaaaactttt	480
gttggtagcg tgactgttgtt aaatggccag ttgaagctag gctcaaagag tattattgg	540
tctgggtcgg ttgtaatttag aaatatacca agtaatgttg tagttgctgg gactccaaca	600
agattaatttta gggggaatga atga	624

&lt;210&gt; 26

&lt;211&gt; 576

&lt;212&gt; DNA

&lt;213&gt; Escherichia coli

&lt;400&gt; 26

gtggcgaaga gcgtacccgc aatttttctt gaccgtgatg gcaccattaa tgtcgatcac	60
ggctatgtcc atgagatcga caactttgaa tttatcgacg gtgttattga cgccatgcgc	120
gagctaaaaaa aaatgggctt tgcgctggtg gtagtcacca accagtctgg cattgctcgc	180
ggtaaattta ccgaagcaca gtttgaaaacg ctgaccgagt ggatggactg gtcgctggcg	240
gaccgagatg tcgatctgga tggtatctat tattgcccgc atcatccgca gggtagtgtt	300
gaagagtttc gccaggtctg cgattgccgc aaaccacatc cggggatgct tttgtcagca	360
cgcgattatt tgcataattga tatggccgct tcttatatgg tgggcataa attagaagat	420
atgcaggcag cgggtgcggc gaacgtggga acaaaagtgc tggtgctac gggtaaacct	480
attacacctg aagcagaaaaa cgcggcagat tgggtgttaa atagcctggc agacctgccc	540
caagcgataaaaaaagcagca aaaaccggcg caatga	576

&lt;210&gt; 27

&lt;211&gt; 933

&lt;212&gt; DNA

&lt;213&gt; Escherichia coli

&lt;400&gt; 27

atgatcatcg ttaccggcgg cgcccccttt atccggcagca acatcgtaa agccctgaat	60
gataaaggca tcaccgatat tctggtggtg gacaacctga aagacggcac caagtttg	120
aacctgggtgg atctgaatat cgcagactat atggataagg aagacttcct gatccagatt	180
atggctggcg aagagttcgg cgatgtcgaa gcgatccccc acgaaggcgc gtgctttcc	240

accaccgagt	gggacggcaa	gtatatgatg	gataacaact	atcaatactc	caaggagctg	300
ctgcactact	gcctggagcg	tgaaatcccg	ttcctgtacg	cttctccgc	agccacctac	360
ggcggacgca	cctccgactt	tattgaatcc	cgcgagtagc	aaaaaccgtt	gaacgtctac	420
ggttactcaa	aattcctgtt	tgatgaatat	gttcgccaaa	tcctgccgga	agcgaactcg	480
cagattgtt	gcttccgcta	tttcaacgtt	tatggaccgc	gtgaaggcca	taaaggcagc	540
atggcgagcg	tcgccttcca	tctcaacacc	cagcttaata	acggtgaatc	accgaagctg	600
ttcgaaggta	gcgagaactt	taaacgcgac	ttcgtctatg	ttggcgatgt	ggcagatgta	660
aacctgtggt	tcctggaaaa	tggcgtttcc	ggcatcttca	acctcggcac	cggtcgtgcg	720
gaatccttcc	aggctgttagc	tgatgctacg	ctggcttatac	acaagaaagg	ccagatcgaa	780
taacattccgt	tcccgataa	gctgaaaggc	cgctaccagg	cgttcaactca	ggcagatctg	840
acaaatctgc	gcccggcggg	ttacgacaaa	ccgttcaaaa	ccgttgctga	agggtgtaa	900
gaatacatgg	cctggctgaa	tcgcgacgca	taa			933

<210>	28					
<211>	1434					
<212>	DNA					
<213>	Escherichia coli					
<400>	28					
atgaaagtaa	cgctgccaga	gtttgaacgt	gcaggagtga	tggtggttgg	tgatgtgatg	60
ctggatcgtt	actgg tacgg	ccccaccagt	cgtatctcgc	cggaagcgcc	ggtgc cccgtg	120
gtt aaagtga	ataccatcga	agaacgtccg	ggcggcgcgg	ctaacgtggc	gatgaatatc	180
gtt ctctcg	gtgcta atgc	acgcctggc	gggtt gacgg	gcattgacga	tgcagcgcgc	240
gcgc tgagta	aatctctggc	cgacgtcaac	gtcaa atgcg	acttcgtttc	tgtaccgacg	300
catccgacca	ttaccaaatt	acgggtactt	tcccgcaacc	aacagctgat	ccgtctggat	360
tttgaagaag	gtttcgaagg	tgttgatccg	cagccgctgc	acgagcggat	taatcaggcg	420
ctgagttcga	ttggcgcgct	ggtgctttct	gactacgcca	aaggtgcgc	ggcaagcgta	480
cagcagatga	tccaa ctggc	gcgtaa agcg	ggtgttccgg	tgctgattga	tccaaaaggt	540
accgattttg	agcgctaccg	cggcgctacg	ctgttaacgc	cgaatctctc	ggaattt gaa	600
gctgttgcg	gtaaatgtaa	gaccgaagaa	gagattgtt	agcgcggcat	gaaactgatt	660
gccgattacg	aactctcggc	tctgttagtg	acccg tccg	aacagggtat	gtcgctgctg	720
caaccgggta	aagcgccgct	gcatatgcca	acccaagcgc	aggaagtgt	tgacgttacc	780
ggtgcggcgc	acacggtgat	tggcgtcctg	gcccgaacgc	tggcagcggg	taattcgctg	840
gaagaagcct	gtttctttgc	caatcgccg	gctggcgtgg	tggtcggcaa	actgggaa	900
tccacggttt	cgccgatcga	gctggaaaat	gctgtacgt	gacgtgcaga	tacaggctt	960
ggcgtgatga	ccgaagagga	actgaagctg	gccgtagcgg	cagcgcgtaa	acgtggtaa	1020
aaagtggtga	tgaccaacgg	tgtcttgac	atccgtc acg	ccgggcacgt	ctctt atctg	1080

gcaaatgccc gcaagctggg tgaccgcttg attgttgcgg tcaacagcga tgcctccacc 1140  
 aaacggctga aaggggattc ccgccccgta aacccactcg aacagcgtat gattgtgctg 1200  
 ggccgactgg aagcggtcga ctgggttagtg tcgtttgaag aggacacgccc gcagcgcttg 1260  
 atcgccggga tcttgccaga tctgctggtg aaaggcggcg actataaacc agaagagatt 1320  
 gccgggagta aagaagtctg ggccaacgggt ggcaaggtgt tggtgctcaa ctttgaagac 1380  
 gttgctcga cgaccaacat catcaagaag atccaacagg ataaaaaagg ctaa 1434

<210> 29  
 <211> 1263  
 <212> DNA  
 <213> Escherichia coli  
 <400> 29

atgcttaaac gtctaggtaa agtatttggc cctctagttt gtgtttact attgttggta 60  
 ggattatatac ttgtttttcc tgtttctcag cctcatcatt tagttaagga aaaaaacagt 120  
 gcagtagcgt tgacaaaggc aggtttaaa agcagagttc aaaaagttag agctttcagt 180  
 gatcctaaag ccaattttgt ccctttcttt gttcaagtg agtggtaag atttgatgca 240  
 atgcatccat cagttttagc agaggcttac aaaaggcctt atatccata tcttttaggt 300  
 caaaaagggg cggcttctct gacacaatac tatggcatc aacagattaa aggacaaatc 360  
 aaaaataaaa aagctatcta tgttatttct ccgcaatggt ttgttcgcaa gggagccaa 420  
 aaaggtgctt ttcaaaacta tttcagcaac gatcaaacca ttcgattttt gcaaaatcaa 480  
 acagggacaa cctacgatag gtatgctgct cgtcgattgt taaaattata tcctgaagct 540  
 tctatgtcag atttgataga aaaaagttgca gatggccaa aactatcaa taaagacaaa 600  
 caaagactaa agttaatga ttgggtatTT gagaagacag atgctatTT tagctatcta 660  
 ccactaggaa aaacttataa tcaggtataa atgcctcatg ttggtaaattt accgaaagca 720  
 ttctcatata atcatttatac gcgtattgca tcacaagatg ctaaagttagc aacgagatca 780  
 aatcaatttgcgtattgatga tcgctttac caaacaagaa ttaaaaagca cttaaaaaaa 840  
 ttgaaagggt cacaacgaca tttcaatttactaactaagtccac cagaatttaa tgatttacag 900  
 ttggttctta atgaattctc aaaacaaaat acagatgtcc ttttgcattt accaccagta 960  
 aataaaaaagt ggacagacta cacagggctt gatcaaaaaa tgtatcaaaa atctgtagaa 1020  
 aaaataaaaac accaacttca aagtcaaggt ttcaatcata tctctgacct ttctcgagat 1080  
 ggaggtaagc catactttat gcaagataca atccatTT gttggaaatgg ttggtttagag 1140  
 ctagataagc atatcaatcc attttaaca gaggaaaaca gcaagccaaa ttatcacatt 1200  
 aataataaaat ttttgaagag atcttggca aaatatacag gacgtccaaag tgattacaag 1260  
 taa 1263

<210> 30

<211> 1536  
 <212> DNA  
 <213> Escherichia coli  
 <400> 30

atgatacatg atatgattaa aacaatttag cattttgctg agacacaagg tgattttcca 60  
 gtgtatgata ttttagggg agtccatact tatggacaac ttaaagttaga ctctgactct 120  
 ctagctgctc atattgatag cctaggcctt gttgaaaaat cacctgtctt agtattcggt 180  
 ggtcaagaat atgaaatgtt ggcgacattt gttgcttaa caaagtcagg gcatgcttat 240  
 ataccggttg accaacactc tgcttggat agaatacagg ctattatgac agttgctcaa 300  
 ccaaggccta tcatttcaat tggtaattt cctcttgaag ttgataatgt cccaatccta 360  
 gacgtttctc aagtttcagc tattttgaa gaaaagactc cttatgaggt aacacattct 420  
 gttaaaggtg atgataatta ctatattatt ttcacttcag ggactactgg tttaccaaaa 480  
 ggtgtcaaaa tttcacatga caatttattt agctttacaa attggatgat ttctgatgat 540  
 gagttttcag ttcctgaaag accgcaaatg ttggctcaac cgccatattc atttgactta 600  
 tcagttatgt attgggcacc aacacttagct atgggaggca ccctgtttgc cctaccaaaa 660  
 acagtagtta atgatttcaa aaaactattc gctaccatata atgaattgcc aatacaggtt 720  
 tggacttcga caccatcatt tgctgatatg gcgctactat ctaacgattt caattcagag 780  
 accttgccac agttaacaca ttttatttt gatgggaaag agttaactgt caagactgca 840  
 caaaaacttc gtcaacgttt tccaaaagct cgtatcgta atgcataatgg gccaacagaa 900  
 gcaacagttg ctctatccgc agtagcaatt actgatgaaa tgtagaaac atgcaaacgc 960  
 cttccaaattt gttacactaa agatgactca ccaacgtatg tgattgatga agaaggcat 1020  
 aaattaccaa acggagagca aggtgaaatc attattgctg gaccagcagt atcaaaaggc 1080  
 tatcttaaca atccagaaaaa gacagctgag gcattttcc aattcgaagg tctacctgct 1140  
 taccataccg gtgacttagg aagtatgacc gatgaaggc ttctgcttta cggtggcgt 1200  
 atggatttcc aaattaaatt taacggctat cgtattgaat tagaagatgt ttctcaaaac 1260  
 ttaaacaat cgcagttatgt aaaatcagca gtagcagtgc cacgttataa caaggatcat 1320  
 aaagttcaaa acttatttagc ctatattgtc ttaaaagaag gtgtaaagaga tgattttgaa 1380  
 cgtgatttgg atttgacaaa agcaattaag gaagacttaa aggacattat gatggattac 1440  
 atgatgocat ctaaatttat ctatcgagag gatttacctt tgacaccaaa tggaaaaatt 1500  
 gatatacaaag gtcttatgag cgaggtaaac aagtga 1536

<210> 31  
 <211> 60  
 <212> DNA  
 <213> Escherichia coli  
 <400> 31

tcgtgcaggc caacctgcac aacagagtga tttgattaac gtgtaggctg gagctgcttc 60

<210> 32  
<211> 60  
<212> DNA  
<213> Escherichia coli  
<400> 32

cagggtgctg gcgctcacca tttccggaga cagcttagac acatatgaat atcctcctta 60

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**